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 This dissertation examines key issues for improving hypertension management and the 
implications of recent guidelines for cardiovascular health and disparities. We used multiple data 
sources and study designs to inform our public health recommendations. 
 First, we examined trends in hypertension awareness, treatment, and control from 1999 to 
2016 using National Health and Nutrition Examination Survey (NHANES) data. Awareness, 
treatment, and control increased overall, but primarily between 1999 and 2010. Hypertension 
treatment to control was lower among Blacks than whites. There were gaps at all stages of care 
among younger Hispanics. 
 Second, clinical guidelines emphasize accurate blood pressure (BP) measurement for 
hypertension diagnosis and treatment. Rounding measurements to zero is a common source of 
error. We used National Disease and Therapeutic Index data from 2014 to 2018 to examine BP 
measurements at physician office visits by adults aged ≥18 with treated hypertension. The 
proportion of measurements ending in zero remains high, despite modest decreases among 
systolic (43.0% to 38.1%) and diastolic (44.3% to 39.4%) BP measurements.  
 Third, we examined changes in hypertension control from 2011-2013 to 2016-2017 
among white and Black older adults with treated hypertension in the Atherosclerosis Risk in 
Communities Study. At baseline, 75.4% of whites and 66.0% of Blacks had controlled 
hypertension. While changes were similar by race, Blacks with diabetes or reduced kidney 
function were less likely to be controlled at follow up. Higher BP goals recommended in 2014 for 
older adults and those with diabetes and chronic kidney disease may contribute to these findings 
and differences by race. 
 Finally, we calculated the proportion of cardiovascular events which could be prevented 
if hypertension was treated to the 2017 guideline target (<130/80 mmHg). Using NHANES data 
and parameters from the literature, we estimated 29.0% of events among Blacks and 21.0% of 
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events among whites could be prevented. However, intensive efforts may be required to achieve 
this BP goal.   
 Our findings highlight implementation considerations. Recommended BP measurement 
procedures can be difficult to incorporate into the clinical workflow. Controversy and confusion 
regarding conflicting guidelines may have unintended consequences for patients at increased 
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 Improving the prevention and management of high blood pressure is a leading public 
health challenge and an issue for health equity. Hypertension has been described as one of the 
most important risks to the cardiovascular health of African Americans and also one of the 
greatest opportunities for disease prevention if effectively managed and prevented.1 This 
dissertation focuses on understanding trends in hypertension management by population subgroup 
and the implications of recent hypertension guidelines for racial disparities in cardiovascular 
health. 
 
Disparities in the burden of hypertension in the U.S. 
High blood pressure is a leading modifiable risk factor for cardiovascular disease, the top 
cause of death in the U.S. and around the world.2 Hypertension (blood pressure >140/90 mmHg) 
affects nearly one-third of all U.S. adults. The prevalence of hypertension is significantly and 
persistently higher among non-Hispanic Blacks in the U.S. than other racial/ethnic groups. In 
2015-2016, 40.6% of non-Hispanic Black adults ages 18 and older had hypertension as compared 
with 27.8% of non-Hispanic whites.3 
Among U.S. adults with hypertension, only about half have their blood pressure 
controlled (<140/90 mmHg), a proportion which has not changed since 2010.3 Hypertension 
control is significantly lower among non-Hispanic Blacks than non-Hispanic whites (44.6% vs 
50.8% in 2015-2016).3  
 Racial disparities in hypertension prevention and control contribute to longstanding 
disparities in cardiovascular health outcomes, such as coronary heart disease, stroke, heart failure, 
chronic kidney disease, and deaths from these conditions.4–7 
 
The role of health care in health equity 
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Racial disparities in hypertension emerge at a young age, highlighting the importance of 
primordial prevention to reduce disparities in the incidence of hypertension.1,8 Racial disparities 
in hypertension control and blood pressure-related outcomes, despite comparable levels of 
awareness and treatment of hypertension among whites and blacks, suggests a role for health care 
in addressing disparities,1 which is the focus of this dissertation, recognizing it is necessary to 
address the underlying historical, political, and social determinants of health to truly achieve 
equity.1,9 
Health care systems with racially and ethnically diverse patient populations and in 
diverse practice settings have demonstrated it is possible to increase hypertension control to 70% 
and higher.10–13 Certain health systems have implemented interventions which resulted in 
comparable increases in hypertension control across racial/ethnic groups, which we would expect 
to have greater benefits for those at higher risk of cardiovascular disease, though identifying 
interventions which effectively eliminate disparities in hypertension control is an area of current 
investigation.10  
Common elements of interventions which have improved blood pressure control include 
standardizing blood pressure measurement procedures and implementing guideline-driven 
protocols for hypertension treatment. We focus on blood pressure measurement and clinical 
practice guidelines, and their implications for equity, in the discussion which follows. 
 
Blood pressure measurement  
Accurate blood pressure measurement is central to the diagnosis and management of 
hypertension and its importance is emphasized universally in clinical practice guidelines. 
However, accurate and reliable assessment of an individual’s blood pressure is challenging. 
Blood pressure is inherently variable and variability is further increased when health care 
providers do not follow standardized measurement procedures,14 which can be difficult to 
implement in routine clinical practice.15,16 Inaccurate measurement may result in under- or 
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overtreatment of patients with hypertension, and may be an overlooked barrier to improving 
control of hypertension as providers are more likely to take action on credible high blood pressure 
measurements.17,18  
Therefore, it is important to quantify blood pressure measurement error. One common 
form of systematic measurement error which can easily be assessed in clinical quality 
improvement programs is terminal digit bias, or a preference by the observer to round 
measurements to a specific end digit, most commonly zero.19 It is possible terminal digit 
preference has been reduced in recent years as a result of increased use of automated blood 
pressure devices, which eliminate certain sources of error which can occur during auscultatory 
blood pressure measurement, and national initiatives to improve hypertension control which have 
included a focus on measurement. We examined trends in terminal digit preference as an 
indicator of blood pressure measurement quality in the U.S.  
 
Hypertension treatment recommendations in recent guidelines  
 Evidence-based guidelines promote consistency, objectivity, and accountability, which 
also affects equity of care.20 However, physician do not always adhere to clinical practice 
guidelines.21 Thus, while there is the potential for guideline-driven care to reduce disparities, 
there is also the potential to perpetuate or exacerbate disparities if clinical practice guidelines are 
not implemented consistently. 
There have been three guidelines published in the past two decades with different 
recommendations for the management of hypertension (Table 1). The Seventh Joint National 
Committee (JNC) on the Prevention, Detection, Evaluation, and Management of Hypertension 
published a comprehensive guideline in 2003, which was the standard of care for many years.22 
The JNC7 guideline recommended a treatment goal of <140/90 mmHg for patients with 
hypertension and <130/80 mmHg for those with diabetes or chronic kidney disease.22 In February 
2014, panel members of the eighth JNC published a report which recommended treatment goals 
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of <140/90 mmHg for patients <60 years of age and <150/90 mmHg for patients ≥60 years of 
age, as well as those patients with diabetes or CKD.23  
In 2017, the American College of Cardiology (ACC) and the American Heart Association 
(AHA) published a new guideline which redefined hypertension as blood pressure ≥130/80 
mmHg and recommended treatment to <130/80 mmHg for all patients on medication.16 
 
Potential impact of recent hypertension guidelines on racial/ethnic disparities  
The potential impact of recent hypertension guidelines on racial/ethnic disparities has 
been the subject of debate. Following the release of the 2014 guideline, a minority of the 
Association of Black Cardiologists and several of the guideline authors expressed concern about 
raising the threshold for treatment initiation and treatment goal from 140/90 to 150/90 mmHg 
among those aged ≥60 without diabetes or chronic kidney disease. In addition to concerns about 
the standard of evidence used to inform this recommendation, they cited concerns about potential 
harms among individuals at increased risk for cardiovascular disease, including African 
Americans, individuals with a history of cardiovascular disease, and those with risk factors for 
cardiovascular disease other than diabetes and chronic kidney disease.24,25  
The 2017 ACC/AHA guideline, which recommends a lower blood pressure treatment 
goal regardless of age or comorbidity status could have a large impact on overall cardiovascular 
health in the population. One recent modeling study found achieving the 2017 ACC/AHA 
guideline systolic blood pressure treatment goal could avert 610,000 cardiovascular events 
(340,000 more than the 2014 guideline) and 334,000 all-cause deaths (156,000 more than the 
2014 guideline) among US adults aged 40 years and older.26  
Implementation of the 2017 ACC/AHA guideline recommendations would be expected to 
result in greater benefit for subgroups, including African Americans, with higher blood pressures. 
However, the guideline has not been endorsed by certain primary care societies and there are 
concerns about feasibility of implementation.27 The extent to which the guideline is currently 
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being followed is unknown. There is the potential to exacerbate disparities if lower blood 
pressure treatment goals are implemented differentially, such as more complete implementation 
among those with greater access to care or who are already better managed.  
 To increase understanding of the implications of recent guideline changes for racial 
disparities in hypertension control and cardiovascular disease outcomes, we used observational 
data to examine changes in hypertension control before and after publication of the 2014 
guideline and conducted a modeling study to assess the potential impact of the 2017 guideline.  
 
Study aims  
 This dissertation was intended to address key issues related to improving hypertension 
management in the population and reducing racial disparities through the following specific aims: 
Aim 1. To examine national trends in hypertension prevalence, awareness, treatment, and 
control from 1999-2016 among U.S. adults by age, sex, and race/ethnicity.  
Aim 2. To evaluate terminal digit preference in blood pressure measurement and its 
trends among a nationally representative sample of office-based hypertension treatment 
visits for adults.  
Aim 3. To examine changes in hypertension control before and after publication of the 
2014 hypertension guideline among a community-based cohort of Black and white older 
adults with treated hypertension.  
Aim 4. To investigate the theoretical impact of the 2017 ACC/AHA guideline on racial 
disparities in cardiovascular health outcomes using a simulation study.  
 
Dissertation structure  
 This dissertation includes four chapters dedicated to the study aims and an overarching 
conclusion section. Each of the chapters is formatted as a publishable manuscript. Chapter 1 
describes trends in hypertension prevalence, awareness, treatment, and control and was published 
6 
 
in the American Journal of Epidemiology.28 Chapter 2 quantifies terminal digit preference in 
blood pressure measurements obtained at office visits for hypertension treatment. Chapter 3 
examines changes in hypertension control before and after the 2014 hypertension guideline 
among Black and white older adults with treated hypertension. Chapter 4 examines the potential 
impact of implementing the 2017 ACC/AHA guideline recommendations for hypertension 
treatment on cardiovascular events by race. Additional methodologic detail for each aim can be 
found the Supplement. Finally, the Conclusion provides a synthesis of our findings and proposes 
next steps for further research and public health action.   
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Table 1. Guideline-recommended blood pressure levels for initiation of pharmacotherapy 
and goal blood pressure among those treated with pharmacotherapy. 
 JNC7 (2003) JNC8 (2014) ACC/AHA (2017) 
Population Initiation Goal Initiation Goal Initiation Goal 
General population ≥140/90 <140/90 ≥140/90 <140/90 ≥140/90 <130/80 
Diabetes or CKD ≥130/80 <130/80 ≥140/90 <140/90 ≥130/80 <130/80 
Age ≥60 yrs without 
diabetes or CKD * * ≥150/90 <150/90 * * 
Age ≥65 yrs * * * * ≥130 <130 
High CVD risk† * * * * ≥130/80 <130/80 
*Not addressed. †10-year CVD risk ≥10% by the Pooled Cohort Equations. CVD = 
Cardiovascular Disease. CKD= Chronic Kidney Disease. JNC7= Seventh Joint National 
Committee. JNC8 = Eight Joint National Committee. Not addressed indicates other thresholds 






Chapter 1. Hypertension awareness, treatment and 
control in US adults: Trends in the hypertension control 
cascade by population subgroup (NHANES 1999–2016) 
 
 
American Journal of Epidemiology 2019;188(12):2165–2174. 
 




Examining changes in the hypertension awareness, treatment and control (i.e., the hypertension 
control cascade) by population subgroup can inform targeted efforts to improve hypertension 
control and reduce disparities. We analyzed data from the 1999-2016 National Health and 
Nutrition Examination Survey and examined trends across 6-year periods in hypertension 
awareness, treatment, and control by age, sex and race/ethnicity. We included 39,589 participants 
(16,141 with hypertension). Hypertension awareness, treatment, and control increased from 1999 
to 2016 among all age groups. However, there were few changes after 2010. Across all time 
periods, awareness, treatment, and control were higher among younger women (versus younger 
men), while control was higher among older men (versus older women). Hypertension control 
was persistently lower for blacks than whites of all ages, and awareness, treatment, and control 
were lower among younger Hispanics. There have been few changes in hypertension awareness, 
treatment, and control since 2010. Disparities in hypertension control by sex highlight the need 
for effective interventions among younger men and older women. Concerted efforts are also 
needed to reduce persistent racial/ethnic disparities, particularly to improve treatment to control 





Hypertension (blood pressure ≥140/90 mm Hg) is a leading modifiable risk factor for 
cardiovascular disease, the leading cause of death in the United States and globally.1 Further, 
there are longstanding racial/ethnic disparities in cardiovascular risk factors, particularly 
hypertension.2  
The hypertension control cascade, which includes hypertension awareness, treatment, 
control, has been proposed as a framework for improving blood pressure control in the 
population.3 The proportion of adults with hypertension who have their blood pressure controlled 
(<140/90 mmHg) increased from the late 1990s through 2010 due to both increases in awareness 
of hypertension and treatment to control among those treated.4,5  
However, national data show there has been no change since, and currently, less than less 
than half of all US adults with hypertension have their blood pressure controlled.6 This plateau 
has occurred despite increased knowledge of effective strategies at the organization, provider, and 
patient levels to improve control of hypertension.7 Communities5 and health systems8 around the 
country have demonstrated it is possible to achieve much higher rates of blood pressure control 
and with concerted efforts, it should be possible to reach 70% hypertension control in the 
population.9  
It is unclear whether the recent lack of progress in hypertension control is attributable to a 
lack of progress at a particular stage in the cascade, nor whether patterns are uniform across 
major demographic groups. Previous research has shown that barriers to hypertension control 
differ age, sex, and race/ethnicity.3,10 Additionally, there are a number of contextual changes 
which may have influenced approaches to hypertension management for different patient 
subgroups in recent years. Such changes include increases in the prevalence of obesity and 
diabetes, expanded insurance coverage, and the publication of multiple clinical practice 
guidelines for hypertension.11–14  
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Understanding changes over time in hypertension awareness, treatment, and control 
overall and among different subpopulations can inform targeted efforts to improve hypertension 
management and reduce disparities. We conducted serial cross-sectional analyses among 
participants in the 1999–2016 National Health and Nutrition Examination Survey (NHANES), the 
most recent national data available, to better understand changes in the hypertension control 





NHANES is a population-based survey which uses stratified, multistage probability 
sampling to produce nationally representative estimates for the civilian, noninstitutionalized 
population in the US. The survey includes interview and examination components. Since 1999, 
NHANES data have been released in 2-year data cycles. We analyzed data from 1999–2016. 
 
Study population 
There were 41,511 non-pregnant adults aged ≥25 years who completed the examination 
component of the survey. Participants who did not have at least one blood pressure measurement 
or for whom hypertension status could not be determined (N=2,096) were excluded from all 
analyses. Those with missing data for hypertension status were more likely to be aged 25–44 or 
≥65 (versus in the middle age category), female (versus male), and non-Hispanic black, Hispanic, 
or Other race/ethnicity (versus non-Hispanic white) compared with those for whom hypertension 





 Blood pressure measurements were obtained during the NHANES examination by 
trained physicians using a standard study protocol.15 After the participant rested in a seated 
position for 5 minutes, 3 consecutive auscultatory blood pressure readings were obtained using a 
mercury sphygmomanometer and appropriately sized blood pressure cuff. If a blood pressure 
measurement was interrupted or incomplete, a fourth attempt was made. All available blood 
pressure readings (i.e., up to three measurements) were used to calculate mean systolic and 
diastolic blood pressures.16 Hypertension was defined as mean systolic blood pressure ≥140 




Among those with hypertension, hypertension awareness was defined based on response 
to the question, “Have you ever been told by a doctor or health professional that you had 
hypertension, also called high blood pressure?” Hypertension treatment was defined as self-
reported current antihypertensive medication use based on responses to the questions, “Because 
of your high blood pressure/hypertension, have you ever been told to take prescribed medicine?” 
and “Are you now taking prescribed medicine for high blood pressure?” Hypertension control 
was defined as blood pressure <140/90 mmHg; we assessed hypertension control among all those 
with hypertension and among those who reported antihypertensive medication use. We also 
examined blood pressure levels over time among those with hypertension and those with treated 
hypertension in mutually exclusive categories: <130/80 mmHg, 130/80 to <140/90 mmHg, 
140/90 to <150/90 mmHg, or ≥150/90 mmHg.  
 
Statistical analyses  
Because hypertension prevalence varies by age, analyses were stratified by age, 
categorized as: 25–44, 45–64, or ≥65 years. We combined data into 6-year periods to obtain more 
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statistically stable estimates within subpopulations defined by age, sex, and/or race/ethnicity 
(non-Hispanic white, non-Hispanic black, Hispanic). We estimated the prevalence of 
hypertension, and among those with hypertension, the prevalence of awareness, treatment, and 
control, as well as control among those treated. All analyses were weighted to account for the 
complex survey design and produce results generalizable to the U.S. population aged 25 or older. 
We obtained standard errors using the Taylor series (linearization) method.  
Within age groups, we used linear regression models with an indicator variable for survey 
cycle to assess absolute changes in prevalence in the periods 2005–2010 or 2011–2016 compared 
to 1999–2004. We used a linear combination of regression coefficients to compare estimates for 
2005–2010 to the 2011–2016 period. We included interaction terms to assess whether differences 
by sex or race/ethnicity changed over time. In supplemental analyses, we also examined trends by 
2-year survey cycles.  We used chi-square tests to examine changes across periods by age group 
in the proportion of those with hypertension and those with treated hypertension with blood 
pressure <130/80 mmHg, 130/80-<140/90 mmHg, 140/90-<150/90 mmHg, or ≥150/90 mmHg. 
Participant blood pressure was categorized using the highest category of systolic or diastolic 
blood pressure.  
To examine trends in hypertension control before and after adjustment for other 
individual characteristics, we used logistic regression to obtain predictive margins. Within age 
groups, we calculated the unadjusted prevalence of hypertension control and compared the 
prevalence of hypertension control across time periods using prevalence ratios. We sequentially 
adjusted for demographic characteristics (sex, race/ethnicity, age within age group), clinical 
characteristics (body mass index (BMI) and self-reported diabetes), access to care (insurance 
coverage and having a usual source of care), and hypertension awareness.  Additionally, among 
those who were aware of their hypertension, we adjusted for duration of hypertension. Duration 
of hypertension was calculated based on the participant’s current age and the age at which they 
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were told they had hypertension. Information on duration of hypertension is available for 2007 
onward; for this analysis, we compared hypertension control in 2011–2016 to 2007–2010. 
All analyses were conducted in Stata version 15.1 (StataCorp, College Station, TX) using 
the svy command package to account for the complex survey design. We used a 2-sided p-value 
of 0.05 to define statistical significance. NHANES was approved by the National Center for 





 There were 39,589 participants (16,141 with hypertension) included in our analysis. 
During the study period, there was no significant change in hypertension prevalence in any age 
group (Figure 1, Web Table 1).  
From 1999–2004 to 2011–2016, hypertension awareness, treatment, and control 
increased significantly among all age groups. However, changes primarily occurred between 
1999–2004 and 2005–2010. Hypertension awareness, treatment, and control significantly 
increased from 1999–2004 to 2005–2010 among those ages 45–64 and ≥65. The only significant 
changes from 2005–2010 to 2011–2016 were increases in awareness among those aged 25–44 
and ≥65. Meanwhile, supplemental analyses examining data in 2-year survey cycles showed that 
there was a significant decrease in hypertension control among those aged ≥65 from 2013–2014 
to 2015–2016 (-8.2%). There were also significant decreases in hypertension control among those 
treated from 2013–2014 to 2015–2016, for those aged 25–44 (-10.3%) and aged ≥65 (-8.1%) 
(Web Table 2). 
 
Hypertension control cascade by age group and sex  
14 
 
Among those aged 25–44, hypertension prevalence was significantly lower among 
women than men in all time periods, though this difference was attenuated in the last survey 
period (Web Table 3, Figure 2). However, across all survey periods, hypertension awareness, 
treatment, and control were higher among women than men aged 25-44. Hypertension control 
among those treated was also higher among women than men but this difference was not 
statistically significant.  
For those aged 45–64, hypertension prevalence was lower among women than men in 
2011–2016 (38.2% vs. 43.3%), a significant change from 1999–2004 when there was no 
difference in hypertension prevalence. Hypertension awareness, treatment, and control increased 
among both men and women during the full study period among those aged 45–64. Nonetheless, 
women had higher levels of awareness, treatment, and control in 2005–2010 and 2011–2016. 
Among women aged 45–64, hypertension control and control among those treated significantly 
increased in both survey periods, and the sex difference in hypertension control and treatment to 
control was larger in 2011–2016 versus 1999–2004.  
Among those aged ≥65, the prevalence of hypertension was higher among women than 
men in all periods, though the sex differences were smaller in 2005–2010 and 2011–2016 than in 
1999–2004. Hypertension awareness, treatment, and control increased among both men and 
women aged ≥65 from 1999–2004 to 2011–2016; however, changes primarily occurred from 
1999–2004 to 2005–2010. There were no sex differences in awareness or treatment, but 
hypertension control and control among those treated were lower among women than men aged 
≥65 in all time periods.  
 
Hypertension control cascade by age group and race/ethnicity  
Hypertension prevalence was significantly and consistently higher among blacks than 
whites in all age groups and across all survey cycles (Web Table 4, Figure 3). Awareness and 
treatment were also higher among blacks than whites aged 45–64 and ≥65 at the start of the study 
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period, but there were greater increases in awareness and treatment among whites. By 2011–
2016, differences in awareness and treatment by race were no longer statistically significant 
despite the overall higher prevalence of hypertension in blacks.  
Hypertension control and control among those treated were generally lower for blacks 
than whites aged 25–44 and 45–64 for the duration of the study period. Among those aged ≥65, 
hypertension control was significantly lower among blacks than whites in 2011–2016, while 
control among those treated was generally lower throughout the study.  
Meanwhile, hypertension prevalence was generally similar among Hispanic and white 
adults. Hypertension awareness, treatment, and control were lower among Hispanics than whites 
aged 25–44, though there were increases among younger Hispanics between 2005–2010 and 
2011–2016. Hypertension control and control among those treated were generally lower for 
Hispanics than whites of all ages. 
 
Blood pressure levels by age group 
 In all age groups, there were differences in the distribution of blood pressure levels 
among those with hypertension and treated hypertension during the overall study period (Table 
1). Among those aged 25–44 and 45–64, there were favorable changes from 1999-2004 to 2005–
2010. The only statistically significant change between 2005–2010 and 2011–2016 was among 
those aged 45–64 with treated hypertension.   
 
Trends in hypertension control before and after adjustment for participant characteristics 
 Within age groups, there was little change in the prevalence ratios for hypertension 
control comparing 2005–2010 to 1999–2004, 2011–2016 to 1999–2004, or 2011–2016 to 2005–
2010 after adjusting for demographic factors, clinical characteristics, access to care, or 
hypertension awareness (Web Table 5). Among those who were aware of their hypertension, 
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additionally adjusting for duration of hypertension did not change the prevalence ratios for 




Our investigation of the hypertension cascade by population subgroup showed 
hypertension awareness, treatment, and control increased during the study period, but 
improvements at each stage of the cascade primarily occurred from 1999–2004 to 2005–2010. 
There were few changes at any stage of the cascade after 2010 for any population subgroup.  
Meanwhile, hypertension prevalence remained stable over time across age groups. However, we 
observed persistent disparities among certain population subgroups. Namely, the prevalence of 
hypertension was higher among blacks than whites, among younger men than women, and among 
older women than men.  
Although the proportion of those with hypertension who are aware and treated has 
increased and there is less room for improvement, the lack of recent change highlights the need to 
implement strategies to detect and initiate treatment among those with hypertension. Consistent 
with previous studies, we found awareness of hypertension is lower among younger than middle 
or older age populations, and particularly low among younger men, which may due to lower 
healthcare utilization.17 Additionally, among those with self-reported hypertension, black and 
Hispanic adults are more likely than whites to be uninsured, lack a regular doctor or health care 
provider, and to report being unable to visit a doctor because of cost18 which may account for the 
lower prevalence of awareness in these groups.   
Treatment to control remains a major barrier at the population-level and indeed, there is a 
substantial drop off in the hypertension cascade at this stage. In particular, treatment to control is 
a major barrier among adults aged ≥65. Additionally, we observed non-significant decreases in 
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control and control among those treated from 2005–2010 to 2011–2016 among blacks and 
women aged ≥65. Based on the distribution of blood pressure levels, there is a suggestion of 
potential deintensification of treatment among adults aged ≥65 in the 2011–2016 period, which 
may reflect 2014 guideline recommendations that adults aged 60 and older without comorbidities 
be treated to <150/90 mmHg rather than <140/90 mmHg (see Web Table 7 for guideline-
recommended hypertension treatment goals over time). As NHANES data are cross-sectional, we 
cannot determine whether any change in the proportion of people with blood pressure between 
140/90 and 150/90 mmHg is the result of treatment deintensification among those with previously 
lower blood pressure values or improved treatment among those with higher blood pressure 
values. Our findings warrant further investigation as there is limited research to date on changes 
in clinical practice before and after the 2014 guideline19 and the potential implications for 
disparities.   
Sex differences in hypertension control at younger ages (more favorable for women vs. 
men) and older ages (more favorable for men vs. women) persisted during the study period. 
However, we found that sex differences in hypertension prevalence changed over time. The 
difference in hypertension prevalence narrowed during the study period among those aged 25–44 
(higher prevalence among men than women) and among those aged ≥65 (higher prevalence 
among women than men). Among those 45–64, we found that hypertension prevalence increased 
among men, but not among women. Additionally, we observed a greater increase in hypertension 
control and control among those treated for women aged 45–64 than men. To our knowledge, 
these changes by sex have not been reported previously. Additional studies are needed to 
understand sex differences in treatment patterns and facilitators and barriers to hypertension 
control by age and sex. 
The only narrowing of black-white disparities we observed was whites catching up to 
blacks in terms of awareness and treatment of hypertension among those aged 45–64 and ≥65. In 
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addition, despite some progress from 2005–2010 to 2011–2016, younger Hispanics had 
persistently lower rates of hypertension treatment, control, and control among those treated. 
Among Hispanic adults, the hypertension control cascade may vary by Hispanic/Latino 
background.20 Increased understanding of the hypertension cascade by origin, level of 
acculturation, preferred language, and other factors are needed to inform culturally-appropriate 
interventions to improve blood pressure control.   
Despite population-level changes during the study timeframe, we did not find that factors 
such as obesity, diabetes, insurance coverage, or duration of hypertension explained the stall in 
improving hypertension control. Additionally, education campaigns to warn about the dangers of 
high blood pressure have not led to improvements in hypertension control in the population. In 
the setting of health disparities, it is well-known that targeted efforts are required to achieve 
health equity.21 Targeted efforts in clinical care will be required to reduce observed differences in 
hypertension control by population subgroups.22 Special efforts will be needed to reach younger 
men and younger non-white individuals who access care less often than their respective 
counterparts, but most patients with uncontrolled hypertension have insurance and access the 
health care system.   
In 2017, the American College of Cardiology (ACC) and American Heart Association 
(AHA) released an updated guideline for the prevention, detection, evaluation, and management 
of high blood pressure among adults.23 This guideline redefines hypertension at a lower level of 
blood pressure (≥130/80 mmHg) and recommends treatment to a lower level of blood pressure 
(<130/80 mmHg) for all population subgroups. If clinical and public health efforts actually 
achieve the lower threshold of <130/80 mmHg, the guideline will also increase hypertension 
awareness, treatment, and control to the surveillance definition of <140/90 mmHg. Although 
some professional societies have not endorsed the more stringent treatment goal,24,25 it is 
important to highlight that even by the higher threshold of <140/90 mmHg, many adults have 
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uncontrolled hypertension. It is also important that the new guideline is broadly implemented 
across population subgroups to reduce rather than exacerbate disparities in hypertension control.  
Our study has several limitations. First, because we combined data into 6-year periods to 
improve the stability of prevalence estimates by population subgroup, there may have been 
contextual changes that led to changes in hypertension management on a smaller timescale than 
was our focus. Our supplemental analyses using 2-year data cycles provide some information on 
changes which occurred within the broader 6-year periods used in the main analysis. Second, 
information on awareness and treatment of hypertension is based on self-report, and there may be 
reporting biases. Third, we are not able to ascertain hypertension treatment with lifestyle 
modification, which may be recommended prior to pharmacotherapy. Fourth, we were unable to 
report data for other racial/ethnic groups due to limited sample sizes, nor were we able to report 
data by Hispanic/Latino origin. Our study also has a number of strengths including the large study 
population, standardized blood pressure measurements, and nationally representative study 
design.    
 
Conclusion 
There has been no change in hypertension control overall since 2010, and since then, 
there have been few changes at any stage of the hypertension cascade overall or by age group. 
Thus, barriers to achieving hypertension control and reducing disparities remain. Among younger 
populations, particularly among men and Hispanics, there are gaps in awareness and treatment. 
For most subpopulations, however, the largest drop off in the hypertension cascade is from 
treatment to control. Further, there are disparities in treatment to control by sex and 
race/ethnicity, including for older women as compared to older men and for black and Hispanic 
adults of all ages as compared to their white counterparts. Persistent disparities illustrate 
hypertension remains a priority health equity issue. Targeted, culturally-appropriate approaches to 
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address barriers at specific stages of the hypertension cascade by population subgroup, as well as 
broader efforts to prioritize hypertension control in clinical practice, are needed to resume 







Table 1. Blood Pressure Levels Among All Those With Hypertension and Treated 
Hypertension by Age Group – US Adults Aged ≥25, National Health and Nutrition 
Examination Survey 1999–2016. 
 
 
 1999–2004 2005–2010 2011–2016 P value for χ2 
  (1)  (2)  (3) (2) vs (1) (3) vs (2) (3) vs (1) 
Age and Blood Pressure Among Those with Hypertension, % (SE) 
25–44         0.23 0.14 <0.001 
 <130/80 15.3 (1.8) 21.2 (1.9) 28.4 (2.2)    
 140/90 18.2 (2.2) 17.4 (1.9) 16.2 (1.8)    
 150/90 18.2 (2.2) 18.8 (2.2) 16.8 (1.8)    
 ≥150/90 48.2 (3.3) 42.7 (2.9) 38.6 (2.3)    
45–64       <0.001 0.13 <0.001 
 <130/80 22.2 (1.2) 32.3 (1.4) 37.2 (1.8)    
 140/90 17.1 (1.1) 19.5 (1.1) 18.4 (1.3)    
 150/90 19.4 (1.4) 19.5 (1.2) 17.1 (1.4)    
 ≥150/90 41.3 (1.8) 28.8 (1.2) 27.2 (1.4)    
≥65       <0.001 0.65 <0.001 
 <130/80 17.2 (1.1) 31.3 (1.1) 31.6 (1.5)    
 140/90 14.3 (0.8) 18.0 (0.9) 18.3 (1.1)    
 150/90 21.1 (0.9) 20.0 (1.0) 21.4 (1.1)    
 ≥150/90 47.2 (1.5) 30.7 (1.0) 28.7 (1.4)    
 Among Those with Treated Hypertension, % (SE) 
25–44         0.34 0.14 0.002 
 <130/80 33.1 (3.2) 41.3 (2.7) 50.2 (3.3)    
 140/90 39.5 (3.4) 34.0 (3.1) 28.6 (2.9)    
 150/90 7.3 (1.8) 6.7 (1.6) 4.1 (1.1)    
 ≥150/90 20.0 (2.9) 18.0 (2.1) 17.1 (1.9)    
45–64       <0.001 0.03 <0.001 
 <130/80 35.3 (1.6) 44.1 (1.6) 49.9 (2.0)    
 140/90 27.2 (1.4) 26.6 (1.5) 24.7 (1.6)    
 150/90 11.1 (1.1) 13.0 (0.8) 9.3 (1.1)    
 ≥150/90 26.3 (1.5) 16.3 (1.2) 16.1 (1.1)    
≥65       <0.001 0.83 <0.001 
 <130/80 25.8 (1.5) 39.2 (1.3) 38.5 (1.7)    
 140/90 21.4 (1.1) 22.5 (1.1) 22.3 (1.3)    
 150/90 15.6 (0.9) 14.7 (0.8) 16.1 (1.1)    






Figure 1. Hypertension Prevalence, Awareness, Treatment, Control and Control Among 
Those Treated by Age Group – US Adults Aged ≥25, National Health and Nutrition 






A) US Adults Aged 25–44. Among those with hypertension, hypertension awareness was 
significantly higher (P<0.05) in 2011–2016 as compared to 1999–2004 and 2005–2010. 
Hypertension treatment was significantly higher in 2011–2016 as compared to 2005–2010. 
Hypertension control was significantly higher in 2011–2016 as compared to 2005–2010. 
 
B) US Adults Aged 45–64. Among those with hypertension, hypertension awareness, treatment, 
control, and control among those treated were significantly higher in 2005–2010 and 2011–2016 
as compared to 1999–2004.  
 
C) US Adults Aged ≥65. Among those with hypertension, hypertension awareness was 
significantly higher in 2005–2010 and 2011–2016 as compared to 1999–2004, and higher in 
2011–2016 as compared to 2005–2010. Hypertension treatment, control, and control among those 




Figure 2. Hypertension Control (Left) and Control Among Those Treated (Right) by Age 





A) Hypertension Control Among US Adults Aged 25–44 with Hypertension. Among females, 
hypertension control was significantly higher (P<0.05) in 2011–2016 as compared to 1999–2004. 
Hypertension control was significantly higher among females than males in 1999–2004, 2005–
2010, and 2011–2016.   
 
B) Hypertension Control Among US Adults Aged 45–64 with Hypertension. Among females, 
hypertension control was significantly higher in 2005–2010 and 2011–2016 as compared to 
1999–2004, and in 2011–2016 as compared to 2005–2010. Among males, hypertension control 
was significantly higher in 2005–2010 and 2011–2016 as compared to 1999–2004. Hypertension 
control was significantly higher among females than males in 2005–2010 and 2011–2016. There 
was a larger difference in hypertension control by sex in 2011–2016 as compared to 1999–2004. 
 
C) Hypertension Control Among US Adults Aged ≥65 with Hypertension. Among males, 
hypertension control was significantly higher in 2005–2010 and 2011–2016 as compared to 
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1999–2004.  Among females, hypertension control was significantly higher in 2005–2010 and 
2011–2016 as compared to 1999–2004.  Hypertension control was significantly higher among 
males than females in 1999–2004, 2005–2010, and 2011–2016. 
 
D) Hypertension Control Among US Adults Aged 25–44 with Treated Hypertension. 
 
E) Hypertension Control Among US Adults Aged 45–64 with Treated Hypertension. Among 
females with treated hypertension, hypertension control was significantly higher in 2011–2016 as 
compared to 1999–2004 and 2005–2010. Among males with treated hypertension, hypertension 
control was significantly higher in 2011–2016 as compared to 1999–2004. Among those treated, 
hypertension control was significantly higher among females than males in 2011–2016 and the 
sex difference in hypertension control was significantly different in 2011–2016 as compared to 
1999–2004. 
 
F) Hypertension Control Among US Adults Aged ≥65 with Treated Hypertension. Among males 
and females with treated hypertension, hypertension control was significantly higher in 2005–
2010 and 2011–2016 as compared to 1999–2004. Among those treated, hypertension control was 
significantly higher among males than females in 2005–2010 and 2011–2016. The male-female 
sex difference in hypertension control among those treated was significantly smaller in 2005–





Figure 3. Hypertension Control (Left) and Control Among Those Treated (Right) by Age 
Group and Race/Ethnicity – US Adults Aged ≥25, National Health and Nutrition 




A) Hypertension Control Among US Adults Aged 25–44 with Hypertension. Among whites, 
hypertension control was significantly higher (P<0.05) in 2011–2016 as compared to 1999–2004. 
Among blacks, hypertension control was significantly higher in 2005–2010 and 2011–2016 as 
compared to 1999–2004. Among Hispanics, hypertension control was significantly higher in 
2011–2016 as compared to 1999–2004 and 2005–2010. Hypertension control was significantly 
higher among whites than blacks in 1999–2004 and 2011–2016. Hypertension control was 
significantly higher among whites than Hispanics in 1999–2004, 2005–2010, and 2011–2016. 
 
B) Hypertension Control Among US Adults Aged 45–64 with Hypertension. Among whites, 
blacks, and Hispanics, hypertension control was significantly higher in 2005–2010 and 2011–
2016 as compared to 1999–2004. Hypertension control was significantly higher among whites 
than blacks in 1999–2004, 2005–2010, and 2011–2016. Hypertension control was significantly 




C) Hypertension Control Among US Adults Aged ≥65 with Hypertension. Among whites, blacks, 
and Hispanics, hypertension control was significantly higher in 2005–2010 and 2011–2016 as 
compared to 1999–2004; among Hispanics, hypertension control was also significantly higher in 
2011–2016 as compared to 2005–2010. Hypertension control was significantly higher among 
whites than blacks in 2011–2016. Hypertension control was significantly higher among whites 
than Hispanics in 1999–2004 and 2005–2010, with a larger difference in 2005–2010 than in 
1999–2004.  
  
D) Hypertension Control Among US Adults Aged 25-44 with Treated Hypertension. Among 
those with treated hypertension, hypertension control was significantly higher among whites than 
blacks in 1999–2004, 2005–2010, and 2011–2016, and significantly higher among whites than 
Hispanics in 1999–2004 and 2005–2010.  
 
E) Hypertension Control Among US Adults Aged 45–64 with Treated Hypertension. Among 
whites, blacks, and Hispanics with treated hypertension, hypertension control was significantly 
higher in 2005–2010 and 2011–2016 as compared to 1999–2004. Among those treated, 
hypertension control was significantly higher among whites than blacks in 1999–2004, 2005–
2010, and 2011–2016. Among those treated, hypertension control was significantly higher among 
whites than Hispanics in 1999–2004. 
 
F) Hypertension Control Among US Adults Aged ≥65 with Treated Hypertension. Among 
whites, blacks, and Hispanics with treated hypertension, hypertension control was significantly 
higher in 2005–2010 and 2011–2016 as compared to 1999–2004.  Among those treated, 
hypertension control was significantly higher among whites than blacks in 1999–2004 and 2011–
2016. Among those treated, hypertension control was significantly higher among whites than 




Chapter 2. Digit preference in office blood pressure 
measurements, United States 2014–2018  
 
 






Importance: Accurate blood pressure (BP) measurement is essential for the diagnosis and 
treatment of hypertension, but BP measurement is prone to error. One common source of 
systematic error is terminal digit preference, most often a terminal digit of ‘0’. The increasing use 
of automated BP devices and initiatives to improve hypertension management may have reduced 
terminal digit preference in recent year. 
Objective: To evaluate trends in terminal digit preference among a nationally representative 
sample of office BP measurements among adults with treated hypertension. We hypothesized 
digit preference would decrease over time. 
Design: We conducted a serial cross-sectional study using data 2014 to 2018 from IQVIA’s 
National Disease and Therapeutic Index, a nationally-representative audit of office-based 
physicians.  
Setting: Office-based physicians in the U.S. 
Participants: Patients visits were the unit of analysis. We included all office visits among adults 
aged ≥18 years receiving antihypertensive treatment. 
Exposures: We examined trends by patient sex, age, and race/ethnicity, by physician specialty, 
and by first or subsequent hypertension treatment visit.  
Main Outcome: Proportion of systolic and diastolic BP measurements ending in zero. 
Results: In the absence of bias, the expected percent of BPs with a terminal zero is 10% for 
automated and 20% for manual readings. From 2014 to 2018, there was a decrease in the percent 
of visits with systolic (43.0% to 38.1%) or diastolic (44.3% to 39.4%) BP recordings ending in 
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zero. Trends were similar by patient demographic characteristics. However, there was less 
reduction in terminal digit preference among first (vs subsequent) treatment visits, visits to 
cardiologists (vs primary care physicians), and among visits with systolic BP ≥140 mmHg or 
diastolic BP ≥90 mmHg (vs <140/90 mmHg).  
Conclusions and Relevance: Terminal digit preference remains a common problem, despite 
modest improvement over time. Systematic error contributes to both under- and overtreatment of 
individuals with hypertension. Reducing digit preference is feasible and can improve the accuracy 





Accurate blood pressure (BP) measurement is central to the diagnosis and treatment of 
hypertension.1 Although BP is measured at nearly every clinical encounter, accurate and reliable 
assessment of an individual’s BP is challenging. Blood pressure is inherently variable and 
variability is further increased when health care providers do not follow standardized 
measurement procedures.1 Recommended procedures for accurate BP measurement can be 
difficult to implement in routine clinical practice resulting in inaccurate assessment of BP.2,3 
Measurement error may result in the under- or overtreatment of patients with hypertension.4 
One common form of measurement error is terminal digit bias, or a preference by the 
observer to round measurements to a specific end digit, most commonly zero.5 In ambulatory 
care, BP is assessed with either a manual device using an auscultatory approach or an electronic 
device using an oscillometric approach.1 Without terminal digit bias, approximately 20% of 
measurements with manual and 10% of measurements with automated devices are expected to 
end in zero. However, previous studies report an absolute excess of 1-79% in end-digit zeroes.5 
Prior research shows patients at practices with higher terminal digit preference are less likely to 
have an antihypertensive prescription6 and are more likely to experience an adverse 
cardiovascular event.7  
Terminal digit preference may have decreased in recent years. The restricted use of 
mercury devices, concerns about measurement error with manual BP measurement, and 
discrepancies between in- and out-of-office BPs1 has led to increased use of automated BP 
devices in the past two decades. Though automated BP devices do not eliminate measurement 
error, they may reduce terminal digit preference. Several clinic-based studies have documented a 
reduction in terminal digit preference after the introduction of automated BP devices.7,8 
Additionally, national and global cardiovascular health initiatives emphasize proper BP 
measurement technique, including the U.S. Department of Health and Human Services’ Million 
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Hearts initiative,9 the American Heart Association and American Medical Association’s Target: 
BP,10 the World Health Organization’s Global Hearts initiative,11 Vital Strategies’ Resolve to 
Save Lives,12 and the Accuracy in Measurement of Blood Pressure (AIM-BP) collaborative from 
the World Hypertension League.13 
In this context, we evaluated trends in terminal digit preference among a nationally 
representative sample of office BP measurements among adults with treated hypertension. We 





We used data from IQVIA’s National Disease and Therapeutic Index (NDTI), which 
provides nationally representative data on the patterns and treatment of disease encountered by 
office-based physicians in the continental U.S. Data from the NDTI have been used in other 
studies examining ambulatory care.14,15 The NDTI uses the American Medical Association and 
American Osteopathic Association master lists to sample approximately 4,000 physicians 
quarterly, stratified by geographic region and specialty. For each participating physician, two 
random consecutive workdays are sampled. For each patient seen on those workdays, the 
physician reports all diagnoses and all prescription and non-prescription medications newly 
ordered or previously ordered and continued. Data are weighted to estimate all patient contacts on 
all workdays for all U.S. office-based physicians. 
We identified all office visits from January 1, 2014 to December 31, 2018 among adults 
aged ≥18 years with a recorded diagnosis of hypertension and at which hypertension treatment 
occurred (i.e., adult hypertension treatment visits). Hypertension diagnoses were identified using 
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survey-specific diagnostic codes. Each record of new or continued drug therapy is linked to the 
relevant diagnosis.  
 
Blood pressure measurement and recording 
The BP measurements used in our study are based on the information recorded on the 
survey form for each patient visit. The NDTI survey procedures do not instruct the physician or 
individual taking the BP measurement to use a specific protocol.  
 
Patient and physician characteristics  
Physicians record patient demographic characteristics for each encounter on the survey 
form, including sex, age, and race/ethnicity. Each visit is also characterized by the physician as a 
first or subsequent treatment visit, based on whether the physician has seen the patient previously 
for this episode of the diagnosis. Physician specialty is obtained from the American Medical 
Association and American Osteopathic Association master lists. 
 
Statistical Analyses  
We examined annual trends from 2014 to 2018 in the number of hypertension treatment 
visits and the proportion of such visits with recorded systolic and diastolic BP measurements with 
a terminal digit ‘0.’ We examined trends overall and by patient characteristics and physician 
specialty. We categorized patient sex as male or female, age as 18-59 or ≥60 years, and 
race/ethnicity as white, Black, Hispanic, Asian, or other (race/ethnicity categories used are based 
on those available to physicians on the survey form). We categorized visits as first or subsequent 
treatment visits. We categorized physician-reported specialty as primary care (family practice, 
general practice, or internal medicine), cardiology, or other.   
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We examined the frequency of specific BP values in the dataset and plotted histograms to 
characterize the extent of terminal digit preference across the full range of BP values. We present 
the distributions of systolic and diastolic BP from 2018 as examples of the patterns we observed.  
Then, we examined the proportion of BP values with a terminal zero by BP level. We 
considered the measurement ending in 0 as the midpoint of the interval including all possible end 
digits; for 0 to represent the middle of the interval we used one half of the measurements ending 
in 5 at the lower and upper bound of the interval.16 For example, we calculated the proportion of 
systolic BP measurements of 140 mmHg in the interval from 135 to 145 mmHg, using half of the 
number of 135 and 145 mmHg measurements.  
Next, we examined trends in the proportion of systolic and diastolic BP measurements 
with other end digits. We also calculated the proportion of measurements ending in 1, 3, 7, and 9 
in each year. While there is some evidence observers round measurements to 5,17 measurements 
ending in 1, 3, 7, or 9, are likely only obtained using automated devices.  
In supplemental analyses, we examined trends in the proportion of BP values 
immediately above and below thresholds for hypertension control recommended by clinical 
practice guidelines in use during the study period.3,18,19 Some previous studies have found 
evidence of a preference for values just below target BPs.16,20 We examined trends in the 
proportion of measurements within ± 2-units of 130, 140, and 150 mmHg systolic BP, and within 
± 2-units of 80 and 90 mmHg diastolic BP.16  
All analyses were weighted to generate estimates nationally representative of office visits 






 Between 2014 and 2018, there were approximately 60 million hypertension treatment 
visits annually (Table 1). The majority of hypertension treatment visits occurred among adults 
aged ≥60 years, were for subsequent hypertension treatment, and among primary care physicians. 
In all study years, approximately 60% of visits had a systolic BP measurement <140 mmHg and 
nearly 80% of visits had a diastolic BP measurement <90 mmHg.  
 
Trends in terminal digit preference overall and by subgroup 
In 2014, the proportion of visits with systolic (43.0%) and diastolic (44.3%) BP 
measurements with a terminal zero was higher than expected based on chance alone (Table 2). In 
2018, 38.1% of systolic and 39.4% of diastolic recordings ended in zero. 
Trends in the proportion of systolic and diastolic BP measurements were similar by sex, 
age, and race/ethnicity. The proportion of visits with a systolic or diastolic BP measurement 
ending in zero was generally higher at first (vs subsequent) treatment visits, visits to cardiologists 
(vs primary care and other physicians), and at systolic BP ≥140 mmHg or diastolic BP ≥90 
mmHg. There were also smaller decreases in the proportion of visits with terminal digit zeroes in 
these groups.   
 
Distribution of BP values 
Histograms of systolic and diastolic BP measurements from 2018 are shown in Figure 1. 
Terminal digit zeroes were common across the full range of BP values. The most frequently 
recorded systolic BP value was 130 mmHg, followed by 140 mmHg, and the most frequently 
recorded diastolic BP value was 90 mmHg.   
 
Trends in terminal digit preference by BP level  
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Although systolic BP of 140 mmHg and diastolic BP of 90 mmHg were reported 
frequently, the proportion of BP measurements ending in 0 was lowest around those values 
(Figure 2). Further, the proportion of measurements with a terminal zero generally decreased in 
those intervals during the study period. The proportion measurements with a terminal zero was 
somewhat higher at higher levels of systolic and diastolic BP. 
 
Trends in other terminal digits 
Throughout the study period, even terminal digits were more frequently reported than 
odd (Figure 3). Eight was the second most common end digit after zero. Throughout the study 
period, approximately 14% of systolic BP measurements ended in eight. There was an increase 
from 12.3% to 15.2% in the proportion of diastolic BP measurements ending in eight.  
Five was the most common odd terminal digit. The proportion of systolic BP 
measurements ending in five increased from 4.4% to 6.9%, while the proportion of diastolic BP 
measurements ending in five remained around 4%. There was little change from 2014 to 2018 in 
the proportion of systolic (6.3% to 7.1%) or diastolic (6.4% to 7.2%) BP measurements ending in 
1, 3, 7, or 9.  
 
Trends in blood pressure values around treatment thresholds 
The percentage of systolic BP measurements of 138-139 mmHg was 1.5 times higher 
than the percentage of systolic BP measurements of 141-142 mmHg (Supplemental Table). 
However, these percentages remained relatively stable over time. The proportions of systolic BP 
measurements 2-units below and 2-units above 130 mmHg were similar and remained stable; a 
similar pattern was observed around 150 mmHg.  
Among diastolic BP measurements, the proportion of measurements within 2-units below 
and 2-units above 80 mmHg were similar and there was little change over time. The proportion of 
diastolic BP measurements of 88-89 mmHg meanwhile was approximately two-fold higher than 
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the proportion of diastolic BP measurements of 91-92 mmHg, and the proportion of diastolic BP 




In this serial, cross-sectional analysis of a nationally-representative audit of ambulatory 
care physicians, we identified approximately 60 million office visits for hypertension treatment 
annually between 2014 and 2018. In 2018, 38.1% of systolic and 39.4% of diastolic BP 
measurements recorded at such visits ended in zero. Terminal digit preference remains commo, 
despite an absolute decrease by 5-percentage points from 2014 to 2018 in the percent of systolic 
and diastolic BP measurements with a terminal zero. Additionally, we observed less progress and 
a higher proportion of measurements with a terminal zero among first treatment visits, visits to 
cardiologists, and at higher levels of systolic and diastolic BP.  
There are several factors which may have contributed to the decrease in terminal digit 
preference in our study. First is the increased use of automated BP devices, though we do not 
have information on the devices used. In recent decades, as mercury has been eliminated from 
medical devices and in recognition of the potential for error with auscultatory technique, semi-
automated and automated oscillometric BP devices have become increasingly used in clinical 
practice.1,21 Second is discussion and debate in the field about BP measurement, for example, in 
the context of the 2015 Systolic Blood Pressure Intervention Trial (SPRINT).22 The SPRINT trial 
demonstrated a reduction in cardiovascular events and deaths treating adults with hypertension at 
increased cardiovascular risk to a systolic BP of <120 mmHg versus <140 mmHg.22 The SPRINT 
protocol used automated BP measurement, including unattended automated BP measurement at 
some study sites.23 The trial results subsequently informed hypertension treatment goals in the 
2017 ACC/AHA high blood pressure guideline.3 While it is acknowledged the BPs achieved in 
SPRINT measured with automated BP devices using standardized procedures correspond to 
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higher casual measurement values, discussion about the trial’s measurement protocol may have 
influenced BP measurement procedures in practice.21 Third is increased awareness of the 
importance of proper BP measurement technique as a result of global, national, and local 
initiatives to improve hypertension control.9–13 
Terminal digit preference has implications for patient care across BP levels. Consistent 
with previous studies, we found greater terminal digit preference at higher BPs for patients with 
hypertension.24 One could argue rounding at BPs above guideline-recommended treatment goals 
is not particularly problematic because such patients would be treated regardless of their exact 
BP. However, rounding typically occurs down which could affect the intensity of pharmacologic 
treatment or use of other patient engagement strategies.6,7 The lowest levels of terminal digit 
preference occurred near guideline-recommended thresholds for BP control (eg, systolic BP <140 
mmHg or diastolic BP <90 mmHg) and decreased over time in such intervals. It is possible 
providers obtain higher quality measurements when the BP value is likely to affect treatment 
decisions. However, it is unclear whether this is the case, and misclassification of hypertension 
control may negatively impact patient outcomes. In a prior study conducted in the UK, 
researchers documented an excess of diastolic BP measurements of ‘88’, as well as end digit 
zeroes, and found women with recorded diastolic BP 88-89 mmHg had subsequently higher rates 
of mortality than those with diastolic BP 90-99.20 It appeared observers rounded down or re-
measured BP until they obtained a more favorable value if they thought the patient did not need 
treatment.20 In other studies in the UK, there is evidence of increased preference for the digits just 
below pay-for-performance targets after their introduction (i.e., threshold bias).16,24 While we 
found an increase in the proportion of diastolic BP measurements of 88-89 mmHg in our study, 
we did not otherwise find strong evidence of preference for values immediately below certain 
thresholds. It will be important to continue to monitor preference for terminal zeroes and values 




Our results showing higher terminal digit preference among visits to cardiologists 
warrant further exploration. A limitation of our study is we do not know who measured the BP 
that was recorded. We are not aware of other studies comparing terminal digit preference by 
specialty. However, terminal digit preference has been documented across a range of health care 
settings, including hypertension specialty clinics.25 
In addition to factors related to BP measurement devices and procedures, our study also 
highlights the importance of accurate BP recording. While we believe the use of automated 
devices increased during this time, the proportion of measurements ending in an odd digit other 
than 5 did not change substantially. It is possible observers maintain a preference for even digits 
or intentionally round measurements from automated devices to zero. It is important to better 
understand and address inaccuracies in BP recording. 
The 2017 ACC/AHA high blood pressure guideline issues a strong recommendation for 
use of proper methods for accurate measurement and documentation of BP.3 The guideline also 
notes there is a growing evidence base supporting the use of automated office BP measurements.3 
Automated office BP is similar to mean awake ambulatory BP and home BP, which are more 
predictive of cardiovascular events than casual office BP measurements.26 The guideline stops 
short of formally recommending the use of automated devices in the office setting. Meanwhile, 
the Canadian Hypertension Education Program recommends automated BP measurement as the 
preferred method of office measurement.27 Indeed, there has been a decrease in terminal digit 
preference across Canadian primary care clinics following the adoption of automated office BP 
devices.7 However, terminal digit preference has not been eliminated, possibly due to continued 
use of manual devices even when automated devices are available,7,28 or rounding of automated 
measurements, highlighting implementation considerations for automated office BP 
measurement.21 Regardless of the type of device used, it is important to train and retrain current 
and future health professionals in proper BP measurement technique and to ensure procedures can 
be incorporated into the clinical workflow.2,29 
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 There are several limitations of our study. First, there is no agreed upon “acceptable” 
percentage of terminal digit zeroes. While we expect 10-20% of measurements to end in zero 
without bias, some have considered 10-29% acceptable.30 However, the percentage of BP 
measurements with a terminal zero in our study was still in excess of this range. Second, we do 
not know the type of BP device or the measurement procedures used, including whether multiple 
readings were obtained. Thus, we cannot determine the contribution of increased use of 
automated devices to the overall decrease in terminal digit preference during the study period. 
Additionally, without knowing the type of device, we cannot determine whether a terminal digit 
of 8 reflects the use of a manual device which is marked with only even numbers or a 
“preference” by the observer for a particular value. Third, we also do not know if the BP readings 
recorded on the NDTI survey are the same as those recorded in the patient’s medical record and 
used to inform decisions about patient care; in field settings, the co-authors have observed 
transcript errors related to intentional rounding. Finally, we cannot account for the clustering in 
measurement (or measurement error) which occurs when the same physician reports data for 
multiple patients.  
Our study has several strengths. To our knowledge, this is the first study to document the 
extent of terminal digit preference nationally and trends over time. The data are nationally 
representative of all visits to office-based physicians in the U.S. Additionally, NDTI data are 
available with a short lag time, which enables use of the data to monitor changes in near real-
time.    
 
Conclusion 
 Our work highlights the need to improve the quality of BP measurement in ambulatory 
settings. To better understand the determinants of terminal digit preference, it would be useful to 
understand the BP devices currently used in practice for screening and diagnosis of hypertension, 
and to monitor the response to hypertension treatment.28 It is possible to reduce terminal digit 
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preference through the use of automated devices, clinical training, and support.2 U.S. guidelines 
could more strongly recommend the use of automated BP devices in the office setting. Regardless 
of the type of device used, accurate BP recording and reporting is critical to patient care. Finally, 
it will be important to continue to monitor trends in terminal digit preference as clinical quality 
measures and pay-for-performance programs are implemented to ensure other biases do not 
occur. Terminal digit preference remains pervasive, but can feasibly be reduced to improve the 







Table 1. Characteristics of office-based hypertension treatment visits – National Disease 
and Therapeutic Index, 2014–2018. 
 
2014 2015 2016 2017 2018 
Total visits (N, millions) 64.5 60.7 58.7 63.7 67.7 
Sex, % 
     
Male 50.4 51.9 52.7 53.3 54.0 
Female 49.6 48.1 47.3 46.7 46.0 
Age, % 
     
Age <60 41.5 41.2 40.4 38.5 38.0 
Age ≥60 58.5 58.8 59.6 61.5 62.0 
Race/ethnicity, % 
     
White 70.8 71.2 69.9 68.4 68.8 
Black 17.5 17.2 17.5 17.4 16.7 
Hispanic 6.1 5.7 6.0 6.3 6.7 
Asian 4.9 5.2 5.5 5.5 6.1 
Other 0.8 0.6 1.1 2.4 1.6 
Visit type, %      
First treatment visit 16.1 16.9 17.3 18.0 20.3 
Subsequent treatment visit 83.9 83.1 82.7 82.0 79.7 
Physician specialty, %  
     
Cardiology 9.4 9.8 10.2 10.0 10.0 
Primary care 75.3 74.3 72.3 71.6 71.2 
Other 15.3 15.9 17.6 18.4 18.8 
Blood pressure level, %       
SBP <140 mmHg 60.3 61.6 59.6 58.8 59.4 
SBP ≥140 mmHg 39.7 38.4 40.4 41.2 40.6 
DBP <90 mmHg 78.2 78.5 77.4 78.4 77.5 
DBP ≥90 mmHg 21.8 21.5 22.6 21.6 22.5 
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Table 2. Percentage of office-based hypertension treatment visits with blood pressure 
measurements with a terminal digit of zero – National Disease and Therapeutic Index, 
2014–2018. 
Primary care defined as family practice, general practice, or internal medicine.   
 Systolic Blood Pressure Diastolic Blood Pressure 
 
2014 2015 2016 2017 2018 2014 2015 2016 2017 2018 
Overall, % 43.0 41.7 39.0 38.0 38.1 44.3 42.7 40.9 38.5 39.4 
Sex, %           
Male 43.6 42.2 39.1 37.3 39.1 43.5 41.5 40.8 37.4 39.5 
Female 42.2 41.0 38.9 38.8 36.8 45.0 43.7 41.0 39.8 39.3 
Age, %           
Age <60 40.7 41.0 39.3 37.0 38.5 41.9 41.7 39.0 36.8 37.5 
Age ≥60 44.6 42.2 38.8 38.6 37.8 46.0 43.4 42.3 39.6 40.6 
Race/ethnicity, %           
White 43.2 42.1 39.5 38.5 39.4 45.0 42.5 41.1 38.9 40.2 
Black 43.5 39.6 36.2 37.4 33.9 41.9 41.1 37.6 37.0 37.1 
Hispanic 40.7 42.1 39.5 38.7 35.9 44.0 44.2 44.0 39.1 37.8 
Asian 44.3 41.7 38.7 37.3 36.7 46.1 46.4 44.4 40.5 40.3 
Other 38.9 36.1 44.8 27.8 36.8 36.3 47.2 44.5 33.6 33.7 
Visit type, %           
First treatment visit 44.7 45.2 39.9 42.1 42.9 46.2 45.4 39.5 40.2 42.3 
Subsequent treatment visit 42.7 41.5 38.9 37.1 36.8 44.2 42.6 41.2 38.2 38.7 
Physician specialty, %            
Cardiology 48.6 45.5 44.2 43.2 44.5 49.7 49.4 50.9 50.3 51.0 
Primary care 42.6 42.1 38.5 37.4 38.4 44.3 42.8 41.1 37.0 39.0 
Other 41.2 37.6 37.9 37.5 33.5 41.0 38.1 34.6 38.1 34.7 
Blood pressure level, %            
SBP <140 mmHg 37.4 36.6 33.7 33.0 32.6 — — — — — 
SBP ≥140 mmHg 51.5 49.8 46.8 45.0 46.1 — — — — — 
DBP <90 mmHg — — — — — 41.1 39.4 36.9 33.5 34.7 






Figure 1. Distribution of systolic (top) and diastolic (bottom) blood pressure measurements 






Figure 2. Proportion of systolic (top) and diastolic (bottom) blood pressure measurements 
with an end-digit zero, by blood pressure level – Hypertension treatment visits 2014–2018. 
SBP = systolic blood pressure. 
DBP = diastolic blood pressure. 
 
Figures report the proportion of measurements ending in zero in the specified interval. Each 
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Figure 3. Trends in systolic (top) and diastolic (bottom) blood pressure measurement end 
digits – Hypertension treatment visits 2014–2018.  
 
SBP = systolic blood pressure.  
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Chapter 3: Changes in hypertension control in a 
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Background: Hypertension guidelines published in 2014 raised treatment goals in older adults.  
Objectives: To examine and compare changes in hypertension control (systolic blood pressure 
<140 mmHg) among Black and white older adults with treated hypertension.   
Methods: We included 2,250 participants aged 71-90 in the Atherosclerosis Risk in Communities 
(ARIC) Study with treated hypertension in 2011-2013 (baseline), present in 2016-2017 (follow 
up). We assessed predictors of change in hypertension control using logistic regression.  
Results: Among whites, 75.4% at baseline and 59.4% at follow up had controlled hypertension. 
Among Blacks, 66.0% at baseline and 56.5% at follow up had controlled hypertension. One-third 
of whites and Blacks with controlled hypertension at baseline developed uncontrolled 
hypertension. Predictors included older age [odds ratio (OR) 1.30 per 5 years, 95% confidence 
interval (CI) 1.14-1.48], female sex (OR 1.60, 95% CI 1.25-2.06), and reduced kidney function 
among whites (OR 1.32, 95% CI 1.00-1.75), and hypertension duration (OR 1.23 per 5 years, 
95% CI 1.05-1.44) and diabetes among Blacks (OR 1.92, 95% CI 1.27-2.92). Among those 
uncontrolled at baseline, ~40% were controlled at follow up. White females (OR 0.45, 95% CI 
0.29-0.68) and Blacks with reduced kidney function (OR 0.44, 95% CI 0.22-0.87) had lower odds 
of control.  
Conclusions:  Changes in hypertension control were similar in whites and Blacks. However, 
Blacks with diabetes or reduced kidney function were less likely to have hypertension control at 
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follow up. Higher treatment goals may have contributed to these findings and unintended 









Hypertension is common in older persons, but treatment goals in this population are 
widely debated. Clinical practice guidelines for hypertension management seek to balance the 
benefits of blood pressure-lowering therapy with the potential for adverse events. However, 
recent recommendations from leading professional societies are conflicting. The JNC7 guideline 
published in 2003 recommended treating hypertension to a goal of <140/90 mmHg among the 
general population and to <130/80 mmHg for those with diabetes or chronic kidney disease.1 In 
2014, panel members of the JNC8 committee recommended treatment to <150/90 mmHg for 
adults aged 60 years or older without diabetes or chronic kidney disease and to <140/90 mmHg 
for all other patients.2 However, not all of the panel members agreed with the higher treatment 
goals.2,3 Several panel members expressed concern that raising the systolic blood pressure (SBP) 
threshold for older adults could undo progress to reduce cardiovascular disease and could have a 
disproportionate negative impact on patients at highest cardiovascular risk, such as African 
Americans, those with a history of cardiovascular disease, and those with multiple risk factors.2,3 
The Association of Black Cardiologists echoed these concerns and cautioned that an unintended 
consequence may be to worsen Black-white disparities in cardiovascular outcomes and life 
expectancy.4 
In 2015, the Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated treating 
high-risk adults without diabetes to SBP to <120 mmHg as compared with <140 mmHg resulted 
in lower rates of cardiovascular events and deaths.5 An analysis restricted to trial participants ages 
75 and older found similar results, including benefit among those who were frail.6 There was no 
difference across trial arms in the rate of serious adverse events.6  
Influenced by the results of SPRINT, the American College of Cardiology (ACC), 
American Heart Association (AHA) and 9 other professional societies recommended in 2017 that 
adults aged ≥65 be treated to SBP <130 mmHg.7 Meanwhile, the American College of Physicians 
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and American Academy of Family Physicians continue to endorse a treatment goal of <150/90 
mmHg among adults aged ≥60 and have published their own clinical practice guideline.8 
Racial disparities in hypertension and blood pressure control in the US are present at all 
ages, including older ages, despite comparable or higher levels of awareness and treatment among 
blacks and whites.9 In the context of conflicting guidelines, it is critical to characterize those 
factors that influence hypertension control and changes in control across subgroups, as these may 
contribute to disparities in the population.10  
There are few community-based cohorts of older adults with contemporary, repeat blood 
pressure measurements that provide an opportunity to evaluate recent changes in the management 
of hypertension. The Atherosclerosis Risk in Communities (ARIC) Study, which enrolled Black 
and white adults from four U.S. communities, conducted examination visits in 2011-2013 and 
2016-2017 when participants were aged 71-90 and 75-94, respectively. Our objectives were to 
examine and compare changes in hypertension control in older Black and white adults, and to 





 The ARIC Study included 15,792 participants from Forsyth County, North Carolina, 
Jackson, Mississippi, Minneapolis, Minnesota, and Washington County, Maryland aged 45-64 at 
the first study visit in 1987-1989.11 Follow up visits have been conducted in 1990-1992, 1993-
1995, 1996-1998, 2011-2013, and 2016-2017. An institutional review board at all study sites and 
the University of North Carolina (ARIC coordinating center) approved all procedures. All 
participants provided written informed consent. 
 For the present analysis, the 2011-2013 study visit (visit 5) served as the baseline. Our 
primary analysis included those participants with treated hypertension in 2011-2013 who also 
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attended the 2016-2017 study visit (visit 6) (Supplemental Figure 1). There were 6,538 total 
participants who attended visit 5. We excluded participants who were nonwhite or nonblack 
(n=18); missing hypertension status, SBP measurements, or self-reported antihypertensive 
medication use (additional n=146); and missing covariates of interest (additional n=837). Among 
this population, we identified those with a doctor’s diagnosis of hypertension and who self-
reported antihypertensive medication use in the past 4 weeks. Among Black and white 
participants in 2011-2013, 74.6% had hypertension, and among those, 90.9% reported 
antihypertensive medication treatment. Of the 3,752 participants with treated hypertension in 
2011-2013, 2,250 were present in 2016-2017 and comprised our study sample.  
In secondary analyses, we examined antihypertensive medication use among those 
participants who brought all of their medications to the 2011-2013 and 2016-2017 study visits 
(n=37 without medications at both visits).  
 
Outcome 
At the study visits in 2011-2013 and 2016-2017, blood pressure measurements were 
obtained using the same, standardized procedures. In brief, each participant had their blood 
pressure measured using an automated sphygmomanometer, the Omron HEM 907 XL, with an 
appropriately-sized cuff. After five minutes of rest, the device took three serial measurements. 
The mean of the second and third SBP readings was used for all analyses. We focused on SBP 
given the independent association with cardiovascular disease outcomes and the emphasis on SBP 
thresholds for older adults.6,7 We defined controlled hypertension at baseline as SBP <140 mmHg 
and uncontrolled hypertension as SBP ≥140 mmHg.  
We classified individuals as having controlled or uncontrolled hypertension at baseline 
and then ascertained hypertension control status at the follow-up visit. Those with SBP <140 
mmHg at baseline could be classified as having controlled (SBP <140 mmHg) or uncontrolled 
hypertension (SBP ≥140 mmHg) at follow up. Similarly, those with SBP ≥140 mmHg at baseline 
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could be classified as having uncontrolled hypertension (SBP ≥140 mmHg) or controlled 
hypertension (SBP <140 mmHg) at follow up.  
In secondary analyses, we assessed antihypertensive medication use based on 
medications brought to the visits and corresponding scanned UPC codes. We calculated the total 
number of antihypertensive medications at baseline and follow-up, and change in the total 
number of antihypertensive medications, for each participant. For combination therapies, each 
drug in the combination was counted as a unique medication (i.e., two-drug single pill 
combinations were counted as two medications).  
 
Participant characteristics of interest 
 Participant characteristics were assessed at the 2011-2013 study visit unless otherwise 
noted. We included factors associated with hypertension control or which we hypothesized could 
influence clinical-decision making about hypertension treatment goals. Age, sex, and race were 
self-reported. Years of education were self-reported at the initial ARIC visit in 1987-1989 and 
categorized as less than high school graduate; high school graduate or vocational school; college, 
graduate or professional school.   
The Short Physical Performance Battery (SPPB) was used to assess physical functioning. 
The SPPB includes three components, chair stands, standing balance, and gait speed. Each 
component is scored from 0-4 with a possible range of composite scores from 0-12. We defined 
poor physical function as an SPPB score ≤6.12 Frailty was assessed using a previously validated 
measure and defined as ≥3 of the following criteria: low strength, low energy, slow walking 
speed, low physical activity, or unintentional weight loss.13 Those who met 1-2 criteria were 
considered pre-frail. In all analyses, we compared participants who were frail or pre-frail with 
those who were not frail.  
Cognitive status was determined by expert committee review according to procedures 
established by the ARIC Neurocognitive Study, which added dementia surveillance and a 
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comprehensive cognitive exam to the ARIC Study beginning in 2011.14 Participants were 
categorized as having normal cognition, mild cognitive impairment (MCI) or dementia. We 
grouped participants with MCI or dementia into one category for analysis due to the low 
prevalence of dementia in our sample and compared such individuals to those with normal 
cognitive status. We defined current depressive symptoms based on a score ≥9 on the 11-item 
Center for Epidemiologic Studies Depression (CES-D) scale.15,16  
Medication adherence was assessed using the Morisky scale and scores were categorized 
as “low,” “intermediate,” or “high” based on established cut points.17 Questions on the Morisky 
scale were not asked in the context of antihypertensive medications specifically, rather about 
adherence to all medications. Hypertension duration was determined based on the time elapsed 
between the date of doctor’s diagnosis, medication use, or elevated blood pressure and the 2016-
2017 study visit date. If a participant had prevalent hypertension at the first ARIC study visit in 
1987-1989, we considered the first study visit as the time of hypertension onset as we did not 
have prior information.    
Body mass index (BMI) was calculated as weight in kilograms (kg) divided by height in 
meters squared (m2). BMI was then categorized as <25 kg/m2 (normal BMI), 25 to <30 kg/m2 
(overweight), or ≥30 kg/m2 (obese). Diabetes was defined as hemoglobin A1c ≥6.5 %, or using 
medication for diabetes, or self-reported diagnosis of diabetes. Reduced kidney function was 
defined as creatinine-based estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2. 
Prevalent coronary heart disease, stroke, and heart failure were defined based on self-report of an 
event prior to the first ARIC study visit or an adjudicated event prior to the 2011-2013 visit.  
 
Statistical analysis 
 We compared baseline characteristics of participants with treated hypertension by race 
using t-tests for continuous variables and chi-square tests for categorical variables. In a 
supplemental analysis to better understand losses to follow up among those with treated 
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hypertension in 2011-2013, we compared the characteristics of those who were present and 
absent in 2016-2017 using t-tests and chi-square tests.  
Next, we examined the distribution of SBP values among Black and white participants; 
we compared mean SBP values and the proportion with SBP <140 mmHg among Black and 
white participants. Given the 2017 ACC/AHA guideline recommends SBP <130 mmHg, we also 
examined the proportion of white and Black participants with treated hypertension who had 
achieved this more stringent SBP goal.  
We calculated prevalence ratios for participant characteristics associated with SBP <140 
mmHg and SBP <130 mmHg at baseline, stratified by race and adjusted for age and sex, using 
Poisson regression with robust variance estimates. A priori, we stratified regression models by 
race as we hypothesized there may be racial differences in associations between participant 
characteristics and hypertension control. We tested for differences in associations among Blacks 
and whites using models which included an interaction term between race and the characteristic 
of interest.  
 Among individuals with SBP <140 mmHg at baseline, we examined the percentage who 
remained controlled at follow up and the percentage who developed uncontrolled hypertension, 
stratified by race. Among Blacks and whites, we compared participant characteristics for those 
who remained controlled and those who developed uncontrolled hypertension at follow up. 
Among those with SBP ≥140 mmHg at baseline, we examined the percentage of individuals who 
had controlled hypertension at follow-up and the percentage who remained uncontrolled, and 
compared participant characteristics by race.  
Next, we used logistic regression to evaluate the associations of each participant 
characteristic of interest with change in hypertension control status from baseline. For those with 
SBP <140 mmHg at baseline, we calculated odds ratios for the development of uncontrolled 
hypertension at follow up. For those with SBP ≥140 mmHg at baseline, we calculated odds ratios 
for controlled hypertension at follow up. We stratified our models by race and controlled for age, 
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sex, and baseline SBP. We again tested for differences in associations by race by including 
interaction terms between race and the characteristic of interest.   
 Finally, among participants with available data on antihypertensive medications brought 
to the study visits, we examined the mean number of medications at baseline and follow up. We 
tested differences in means using paired t-tests. All analyses were conducted using Stata version 




 At baseline, Black participants were younger, but had a longer mean duration of 
hypertension than whites (Table 1). Blacks were more likely than whites to be female, have less 
education, poor physical functioning, depressive symptoms, lower medication adherence, and 
generally had a higher prevalence of cardiovascular disease and its risk factors. White participants 
were more likely than blacks to have reduced kidney function. Characteristics of participants who 
did and did not attend the 2016-2017 visit are found in Supplemental Table 1. 
 
Baseline Results 
At baseline, mean SBP was lower among whites than Blacks (129.0 vs 134.3 mmHg, p 
<0.001) (Figure 1). At baseline, 75.4% of whites and 66.0% of Blacks had SBP <140 mmHg (p 
<0.001), while 53.3% and 43.4% of whites and Blacks, respectively, had SBP <130 mmHg (p 
<0.001). Black participants were, on average, taking more antihypertensive medications than 
whites (2.53 vs 2.18, p <0.001).  
 Among white participants at baseline, women, older participants, and those with longer 
hypertension duration were less likely to have SBP controlled to <140 mmHg (as indicated by 
prevalence ratios <1.00; Table 2). Among Black participants, women and those with longer 
hypertension duration were less likely to have SBP controlled to <140 mmHg, while those with 
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obesity were more likely to have SBP <140 mmHg. Associations were generally similar for more 
intensive SBP control (ie, SBP <130 mmHg), though whites with coronary heart disease or heart 
failure had a higher prevalence of SBP <130 mmHg. 
 
Follow-up Results 
 At follow up (Figure 1), mean SBP was 136.0 mmHg among whites and 137.9 mmHg 
among blacks (p = 0.04). At follow up, 59.4% of all white participants and 56.5% of all Black 
participants had SBP <140 mmHg (p=0.20). Among those with controlled hypertension at 
baseline, approximately one-third of both whites and Blacks had uncontrolled hypertension at 
follow up (Figure 2). Among those with uncontrolled hypertension at baseline, 36.1% of whites 
and 38.9% of Blacks subsequently had their hypertension controlled at follow up. Descriptive 
characteristics of Black and white participants by change in hypertension control status from 
baseline to follow up are presented in Supplemental Tables 2 and 3.  
Among whites with SBP <140 mmHg at baseline, older age, female sex, and reduced 
kidney function were associated with higher odds of uncontrolled SBP at follow-up (indicated by 
odds ratios >1.00; Table 3). Among blacks, longer hypertension duration and diabetes were 
associated with higher odds of uncontrolled SBP at follow-up. There was a significant interaction 
between diabetes and race, indicating Blacks with diabetes were significantly more likely than 
whites to have uncontrolled hypertension at follow-up (p-value for interaction = 0.009).  
Among those with SBP ≥140 mmHg at baseline, white females and Blacks with reduced 
kidney function had lower odds of SBP control at follow up (indicated by odds ratios <1.00; 
Table 4). Blacks with reduced kidney function were significantly less likely than whites to have 
controlled hypertension at follow up (p-value value for interaction = 0.004). 
From 2011-2013 to 2016-2017, the mean number of antihypertensive medications per 
participant decreased from 2.18 to 2.11 (mean difference = -0.07, p = 0.004) among whites; there 






Among older adults with treated hypertension at baseline, SBP was lower for whites than 
Blacks, and a greater proportion of whites than Blacks had SBP controlled to <140 mmHg or to a 
more stringent target of <130 mmHg. While there was greater cumulative exposure to 
uncontrolled hypertension among blacks during the study period, conditional on baseline 
hypertension control status, we found similar changes in control among whites and Blacks. 
Approximately one-third of both whites and Blacks with controlled hypertension at baseline 
developed uncontrolled hypertension at follow up, and just under 40% of whites and Blacks with 
uncontrolled hypertension at baseline had controlled hypertension at follow up. However, there 
were several important differences by race in clinical characteristics associated with subsequent 
controlled and uncontrolled hypertension which may contribute to disparities in cardiovascular 
outcomes among older adults.  
 Among those controlled at baseline, whites and Blacks with reduced kidney function 
were more likely to have uncontrolled hypertension at follow-up, though the association was not 
statistically significant among Blacks. Additionally, Blacks with diabetes had two-fold higher 
odds of incident uncontrolled hypertension as compared to those without diabetes; meanwhile, 
there was no association with diabetes among whites. Among those who were uncontrolled at 
baseline, Blacks with reduced kidney function had lower odds of incident control compared to 
those with normal kidney function; the association was significantly different from that among 
whites. Given the high burden of diabetes and chronic kidney disease among older Black adults in 
the population, combined with the less favorable trends in hypertension management for older 
blacks with such comorbidities, inadequate blood pressure control is an important and potentially 
increasing source of disparities in cardiovascular health. 
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During the time between the two study visits, a new clinical guideline was issued by 
members of the JNC 8 panel recommending higher blood pressure goals for adults aged ≥60 (an 
increase from <140/90 to <150/90 mmHg) and those with diabetes or chronic kidney disease (an 
increase from <130/80 to <140/90 mmHg). Of note, the guideline included a corollary 
recommendation for patients on pharmacologic treatment with lower blood pressures (e.g., <140 
mmHg) without adverse effects, that treatment does not necessarily need to be adjusted.  It is 
unclear whether our findings with respect to changes in hypertension control among those with 
diabetes or reduced kidney function can be attributed to changes in guidelines or whether they 
reflect changes in provider attitudes and practices towards treatment goals as patients with 
comorbidities age. For some patients with a high burden of comorbidities or limited life 
expectancy, higher blood pressure goals may be appropriate based on clinical judgement and 
patient preferences.7 However, the less favorable changes in SBP among Blacks with diabetes 
and chronic kidney diseases are concerning.  
Moving forward, as lower blood pressure treatment goals recommended by the 2017 
ACC/AHA guideline (i.e., SBP <130 mmHg) are implemented in practice, it will be important to 
monitor how hypertension is managed among population subgroups. In our study, we examined 
the proportion of individuals with treated SBP <130 mmHg and cross-sectional associations of 
participant characteristics with SBP treatment to <130 mmHg at the 2011-2013 study visit. More 
than half of white participants had their SBP controlled to <130 mmHg at the baseline visit 
compared with ~40% of black participants. Among both whites and blacks with diabetes or 
chronic kidney disease, we found no difference in the prevalence of SBP <130 mmHg by diabetes 
or chronic kidney disease, despite that the JNC7 guideline recommended a target of <130/80 
mmHg for such patients at the time. While our findings illustrate blood pressure can be managed 
to lower levels among older adults, it will be important to ensure lower treatment goals are 
implemented equitably. This will require targeted efforts to address barriers to hypertension 
control among African Americans, including those which occur in health care (e.g., provider 
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mistrust, cultural competence) and as a result of historical, social, and economic factors.18,19 
Additionally, it will be important individuals at increased cardiovascular risk, such as those with 
diabetes or chronic kidney disease, discuss treatment goals with their physicians. 
We found that Blacks were using more antihypertensive medications than whites at 
baseline, though there was little change in the mean number of medications per person among 
either group at follow-up. It is difficult to determine from our data whether there were additional 
medication adjustments or intensifications that would have been clinically appropriate, especially 
if the BP goal remained <140 mmHg. Further examination of treatment practices among older 
adults using clinic-based information could provide additional insight regarding treatment 
decisions relative to blood pressure levels and patient health status. Although adherence scores 
were lower among Blacks than whites at baseline, a small proportion of participants had low 
adherence scores and this does not appear to be the major driver of differences in blood pressure 
levels by race.  
There are several limitations to our study. First, blood pressure measurements obtained in 
a research setting may differ from those in the clinical setting used to guide treatment decisions. 
There is greater variability in blood pressure measurements obtained in the clinical setting than in 
research studies with standardized measurement protocols.20 Second, the majority of Black 
participants in our study are from one study site in Jackson, Mississippi. Differences by race 
identified in our study may therefore reflect geographic differences in care practices or social 
determinants of health. Third, changes in blood pressure may reflect heterogeneous processes. 
Some decreases in blood pressure could be due to worsening health status as opposed to 
improved hypertension control. Fourth, we were not able to assess whether participants received 
or adhered to lifestyle modifications to reduce blood pressure. Finally, because of the age of 
participants in the cohort, there is substantial loss to follow-up between the two study visits. 
However, study retention is considered high for a cohort of older adults. Additionally, our aim 
was to describe blood pressures among those who were followed.   
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Our study also has a number of strengths. The ARIC Study is a large, community-based 
cohort which includes both Black and white older adults whose health status is well-characterized 
over time. Risk factors were assessed by trained personnel using rigorous, standardized 
measurements including a consistent, high-quality blood pressure measurement protocol across 
the two study visits. Additionally, we were able to leverage ARIC study visits before and after the 
publication of a major hypertension guideline in 2014.  
 
Conclusion  
Our study highlights that Black older adults have a higher cumulative burden of 
uncontrolled hypertension as compared with whites. While prevention at younger ages is critical, 
improving hypertension management in older age is also important for reducing cardiovascular 
disease. We found that blacks with diabetes or chronic kidney disease were less likely to have 
improvements in hypertension management from 2011-2013 to 2016-2017. Higher treatment 
goals recommended in 2014 may have contributed to these findings and unintended differences 
by race. To reduce disparities in cardiovascular disease it is necessary to improve hypertension 
care among such subgroups, including efforts to address clinical and social factors which 
influence hypertension control. The lower level of SBP recommended by the 2017 ACC/AHA 
guideline affords an opportunity to focus on reducing blood pressure for populations at high risk 






Table 1. Characteristics of older adults with treated hypertension in 2011–2013, by race.  
 
White Black p-value 
N (%) 1600 (71.1%) 650 (28.9%)  
Age, mean years (SD) 75.1 (4.7) 74.0 (4.7) <0.001 
Female sex 54.4% 71.4% <0.001 
Education     
Less than high school  9.5% 22.8% <0.001 
High school or vocational school 45.6% 32.2%  
College or higher 44.9% 45.1%  
Poor physical function  7.4% 22.3% <0.001 
Pre-frail or frail  50.2% 53.8% 0.12 
Mild cognitive impairment or dementia 19.1% 17.7% 0.45 
Depressive symptoms 5.1% 9.4% <0.001 
Medication adherence    
High 61.1% 56.2% <0.001 
Intermediate 37.6% 39.2%  
Low 1.3% 4.6%  
Hypertension duration, mean years (SD) 16.3 (7.3) 19.2 (6.5) <0.001 
BMI category (kg/m2)    
<25 20.1% 11.7% <0.001 
25-<30 41.2% 37.1%  
≥30 38.7% 51.2%  
Diabetes 27.8% 42.9% <0.001 
eGFR <60 mL/min/1.73 m2 30.1% 24.9% 0.013 
Prevalent coronary heart disease 18.9% 9.2% <0.001 
Prevalent stroke 3.1% 5.2% 0.017 
Prevalent heart failure 11.6% 18.2% <0.001 




Table 2. Characteristics associated with systolic blood pressure <140 mmHg and <130 
mmHg among older adults with treated hypertension in 2011–2013, by race. 
 
SBP <140 mmHg SBP <130 mmHg 
Prevalence ratio (95% CI)* White Black P† White Black P† 
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*Prevalence ratios adjusted for age and sex. A prevalence ratio >1.00 indicates a higher 
prevalence of hypertension control as compared to the reference group. Bold indicates the 
prevalence ratio is significant at p <0.05.  
†P-value for interaction. A p-value for interaction <0.05 indicates a statistically significant 
difference in the association by race.  




Table 3. Odds ratios for uncontrolled systolic blood pressure in 2016–2017 among white and 
black participants with controlled systolic blood pressure in 2011–2013. 
 
Whites Blacks P-value 
for 
interaction  
OR (95% CI)* OR (95% CI)*  
Age, per 5 years 1.30 (1.14-1.48) 1.14 (0.92-1.42) 0.31 
Female (vs Male) 1.60 (1.25-2.06) 1.20 (0.77-1.86) 0.25 
Education (vs Less than high school 
graduate) 
  0.24 
High school or vocational school 1.13 (0.73-1.75) 0.87 (0.50-1.54)  
College or higher 0.78 (0.50-1.22) 0.96 (0.57-1.62)  
Poor physical function (vs Normal) 1.25 (0.78-2.02) 0.86 (0.52-1.42) 0.18 
Pre-frail or frail (vs Not frail) 1.23 (0.95-1.58) 1.32 (0.88-2.02) 0.93 
Mild cognitive impairment or dementia 
(vs Normal) 
1.24 (0.90-1.70) 1.56 (0.91-2.65) 0.55 
Depressive symptoms (vs No) 1.04 (0.59-1.82) 1.46 (0.71-3.00) 0.47 
Medication adherence (vs High)   0.39 
Intermediate 0.91 (0.70-1.18) 1.27 (0.83-1.96)  
Low 2.14 (0.74-6.21) 1.77 (0.68-4.61)  
Hypertension duration, per 5 years 1.03 (0.95-1.12) 1.23 (1.05-1.44) 0.06 
BMI category, kg/m2 (vs <25)   0.23 
25-<30 0.88 (0.63-1.24) 0.90 (0.44-1.82)  
≥30 0.83 (0.58-1.17) 0.54 (0.27-1.10)  
Diabetes (vs No) 1.03 (0.78-1.36) 1.92 (1.27-2.92) 0.009 
eGFR <60 mL/min/1.73 m2 (vs ≥60) 1.32 (1.00-1.75) 1.47 (0.92-2.35) 0.76 
Prevalent coronary heart disease (vs No) 1.37 (0.99-1.90) 0.95 (0.45-2.00) 0.45 
Prevalent stroke (vs No) 1.48 (0.74-2.95) 1.82 (0.75-4.45) 0.70 
Prevalent heart failure (No) 0.93 (0.62-1.40) 1.02 (0.59-1.73) 0.80 
Systolic blood pressure at Visit 5 1.04 (1.03-1.05) 1.04 (1.02-1.07) 0.90 
*Odds ratios adjusted for age, sex, and systolic blood pressure at Visit 5 (2011-2013). An odds 
ratio >1.00 indicates higher odds of uncontrolled systolic blood pressure in 2016-2017. Bold 
indicates statistically significant at p <0.05. A p-value for interaction <0.05 indicates a 
statistically significant difference in the association by race. BMI = Body Mass Index. CI = 





Table 4. Odds ratios for controlled systolic blood pressure in 2016–2017 among white and 
black participants with uncontrolled systolic blood pressure in 2011–2013. 
 Whites Blacks P-value 
for 
interaction 
 OR (95% CI)* OR (95% CI)*  
Age, per 5 years 1.10 (0.97-1.38) 1.12 (0.84-1.48) 0.92 
Female (vs Male)  0.45 (0.29-0.68) 0.83 (0.43-1.59) 0.11 
Education (vs <Less than high school)   0.53 
High school or vocational school 0.85 (0.40-1.83) 0.62 (0.29-1.31)  
College or higher 0.96 (0.44-2.08) 1.15 (0.57-2.29)  
Poor physical function (vs Normal) 1.49 (0.72-3.08) 1.57 (0.80-3.11) 0.78 
Pre-frail or frail (vs Not frail) 0.97 (0.63-1.49) 0.83 (0.48-1.44) 0.70 
Mild cognitive impairment or dementia 
(vs Normal) 
1.15 (0.69-1.94) 0.55 (0.26-1.16) 0.12 
Depressive symptoms (vs No) 0.71 (0.26-1.95) 0.53 (0.21-1.32) 0.74 
Medication adherence (vs High)   0.41 
Intermediate 0.93 (0.60-1.44) 0.79 (0.45-1.39)  
Low 0.41 (0.05-3.75) 1.69 (0.45-6.34)  
Hypertension, duration per 5 years 1.09 (0.93-1.28) 0.88 (0.68-1.14) 0.15 
BMI category, kg/m2 (vs <25)   0.87 
25-<30 1.41 (0.80-2.50) 0.98 (0.42-2.30)  
≥30 1.52 (0.85-2.73) 1.10 (0.48-2.56)  
Diabetes (vs No) 1.16 (0.72-1.86) 0.81 (0.47-1.41) 0.38 
eGFR <60 mL/min/1.73 m2 (vs ≥60) 1.46 (0.92-2.32) 0.44 (0.22-0.87) 0.004 
Prevalent coronary heart disease (vs No) 1.03 (0.58-1.82) 1.67 (0.68-4.10) 0.56 
Prevalent stroke (vs No) 0.45 (0.12-1.75) 0.69 (0.20-2.42) 0.72 
Prevalent heart failure (vs No) 1.26 (0.68-2.36) 0.77 (0.38-1.60) 0.29 
Systolic blood pressure at Visit 5 0.98 (0.96-1.00) 0.99 (0.97-1.01) 0.36 
*Odds ratios adjusted for age, sex, and systolic blood pressure at Visit 5 (2011-2013). An odds 
ratio >1.00 indicates higher odds of controlled systolic blood pressure in 2016-2017. Bold 
indicates statistically significant at p <0.05. A p-value for interaction <0.05 indicates a 
statistically significant difference in the association by race. BMI = Body Mass Index. CI = 







Figure 1. Systolic blood pressure among older adults with treated hypertension in 2011–
2013 (top) and 2016–2017 (bottom), by race.  
 
 
This figure shows the SBP distributions for white and black adults at Visit 5 (2011-2013) and 
Visit 6 (2016-2017). The mean SBP values and percentage of individuals with SBP <140 mmHg 




Figure 2. Systolic blood pressure control in 2011–2013 and 2016–2017, by race.  
 
The figure shows the percent of white and black individuals with SBP <140 mmHg and ≥140 
mmHg at baseline in 2011-2013. Within baseline categories of baseline hypertension control, we 
show the overall percent of individuals with controlled and uncontrolled hypertension in 2016-












Chapter 4. Implementation of 2017 ACC/AHA 
hypertension guideline: Potential effect on 
cardiovascular events among white and Black adults in 
the United States 
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Introduction: Treating hypertension to lower levels of blood pressure (<130/80 mmHg) 
recommended by the 2017 ACC/AHA hypertension guideline could promote cardiovascular 
health equity. Alternatively, there are concerns about differential implementation, which might 
increase racial disparities. The purpose of our study was to investigate the potential impact of 
treating hypertension according to the 2017 guideline on racial disparities in hypertension control 
and the proportion of cardiovascular disease events which could be prevented nationally in 
different implementation scenarios.   
Methods: We used 2011-2016 data from the National Health and Nutrition Examination Survey 
for Black and white adults aged ≥40 to estimate the prevalence of hypertension, uncontrolled 
hypertension, and eligibility for antihypertensive treatment. We used hazard ratios for the risk 
associated with systolic blood pressure above the treatment goal from a network meta-analysis of 
hypertension treatment trials. We calculated the proportion of events prevented among Blacks 
and whites if all those eligible for antihypertensive treatment had their blood pressure reduced to 
the treatment goal and when less than 100% of individuals were treated to the goal.  
Results: Overall, 74.0% of Blacks and 59.9% of whites had hypertension, 56.3% of Blacks and 
43.0% of whites had uncontrolled hypertension, and 44.4% of Blacks and 31.9% of whites were 
eligible for pharmacologic treatment. If all individuals with hypertension eligible for 
pharmacologic treatment were treated to goal, 29.0% (27.3%, 30.7%) of cardiovascular events 
among Blacks and 21.0% (19.7, 22.3%) of cardiovascular events among whites would be 
prevented. With the same relative reduction in uncontrolled hypertension, the proportion of 
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cardiovascular events prevented is higher among Blacks than whites. However, if the reduction in 
the prevalence of uncontrolled hypertension is more than ~1.4 times higher among whites than 
Blacks, there would be a greater reduction in the proportion of events prevented among whites 
than Blacks, thereby exacerbating disparities.  
Conclusion: Treating hypertension to the 2017 ACC/AHA goal could reduce absolute and 
relative racial disparities in cardiovascular events in the population. However, there is also a 
possibility of exacerbating disparities if implementation occurs differentially by race. Efforts are 





The rate of cardiovascular disease mortality in the United States has decreased 
dramatically from its peak in the 1950s due to advances in prevention and treatment.1,2 While 
rates were comparable among Blacks and whites at the start of the decline, racial disparities in 
cardiovascular disease have since emerged and persisted.3,4 The fundamental social causes of 
disease theory posits it is our expanded ability to prevent and control disease which leads to 
improved population health that also causes disparities as the benefits of public health and 
medical interventions are distributed according to available resources.4  
High blood pressure is a leading modifiable risk factor for cardiovascular disease. High 
blood pressure is more common (40.3% vs 27.8%) and more poorly controlled (44.6% vs 50.8%) 
among non-Hispanic Black than non-Hispanic white adults in the U.S.5 Hypertension has been 
described as one of the most important risks to the cardiovascular health of African Americans 
and also one of the greatest opportunities for disease prevention if effectively managed and 
prevented.6 Reducing racial disparities in hypertension control is therefore a priority for 
cardiovascular health equity.  
In 2017, the American College of Cardiology (ACC) and American Heart Association 
(AHA) published a new high blood pressure guideline which redefined hypertension at a lower 
level of blood pressure (≥130/80 mmHg) and recommended a lower blood pressure goal for those 
treated with antihypertensive medication (<130/80 mmHg).7 The guideline presents opportunities 
and challenges for cardiovascular health and disparities in the population. One recent modeling 
study found achieving the 2017 ACC/AHA guideline systolic blood pressure treatment goal could 
avert 610,000 cardiovascular events and 334,000 all-cause deaths among US adults aged 40 years 
and older.8  
Implementation of the 2017 ACC/AHA guideline recommendations would be expected to 
result in greater absolute and relative benefit for subgroups with higher blood pressures, including 
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African Americans. However, the guideline has not been endorsed by certain primary care 
societies and there are concerns about feasibility of implementation.9 The extent to which the 
guideline has been adopted in clinical practice is unknown. There is the potential to exacerbate 
disparities if lower blood pressure treatment goals are implemented differentially, such as if lower 
treatment goals are more widely used among individuals with greater access to care, who are 
already better managed, or are at lower risk.10  
The population-attributable fraction (PAF) represents the proportion of disease cases in 
the population attributed to a risk factor; it can also be interpreted as the proportion of cases 
which would be theoretically prevented in the population if the exposure was eliminated, 
assuming the exposure is a direct cause of the disease.11 The PAF is determined by the prevalence 
of the exposure and the risk of disease it confers. When the counterfactual scenario is not 
elimination but a reduction of the exposure prevalence, a related concept, the potential impact 
fraction (PIF) can be used to estimate the proportion of cases which would be prevented.12 The 
PAF and PIF are useful for prioritizing public health policy and programs to address modifiable 
risk factors which have the greatest impact on reducing disease.13,14 The objective of our study 
was to examine the potential impact of treating hypertension according to the 2017 ACC/AHA 
guideline on racial disparities in cardiovascular events in U.S. adults using the PAF or PIF in 





 We used data from the National Health and Nutrition Examination Survey (NHANES) 
for the years 2011-2016. NHANES is a population-based survey which uses stratified, multistage 
probability sampling to produce nationally-representative estimates for the civilian, 
noninstitutionalized population in the U.S. The survey includes interview and examination 
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components. NHANES was approved by the National Center for Health Statistics Institutional 
Review Board and informed consent was obtained from all participants. 
 
Study population 
 We included Black and white adults aged 40 years and older from the NHANES 2011-
2016 survey cycles who completed the examination component of the survey (N=6,912). We 
excluded participants who did not have at least one valid blood pressure measurement or for 
whom hypertension status could not be determined. We also excluded those with missing data for 
covariates used to determine their treatment eligibility (diabetes, chronic kidney disease, history 
of cardiovascular disease, and atherosclerotic cardiovascular disease (ASCVD) risk score). The 
final analytic sample included 6,106 participants.  
 
Blood pressure measurement 
  Blood pressure measurements were obtained by trained physicians using a standard 
study protocol during the NHANES examination.15 After participants rested in a seated position 
for five minutes, three consecutive auscultatory blood pressure readings were obtained using a 
mercury sphygmomanometer and appropriately sized blood pressure cuff. If a blood pressure 
measurement was interrupted or incomplete, a fourth attempt was made. We used all available 
blood pressure readings (i.e., up to three measurements) to calculate mean systolic (SBP) and 
diastolic (DBP) blood pressures.16  
 
Hypertension and uncontrolled hypertension  
 Based on the ACC/AHA guideline (Table 1), we defined hypertension as having SBP 
≥130 mmHg, or DBP ≥80 mmHg, or currently taking antihypertensive medications. Current 
antihypertensive medication use was based on self-report. We defined uncontrolled hypertension 




Treatment eligibility  
We determined eligibility for new or additional pharmacotherapy based on the 2017 
ACC/AHA guideline recommendations.7 All individuals with SBP ≥140 mmHg or DBP ≥90 
mmHg were eligible for pharmacotherapy. Individuals with SBP 130-139 mmHg and/or DBP 80-
89 mmHg were considered eligible for pharmacotherapy if they reported current antihypertensive 
medication use (ie, had hypertension) or were aged ≥65 years, had diabetes, chronic kidney 
disease, history of cardiovascular disease, or 10-year ASCVD risk ≥10%. Diabetes was 
determined based on self-reported diagnosis or diabetes medication use. Chronic kidney disease 
was defined based on an albumin-to-creatinine ratio ≥30 mg/g or estimated glomerular filtration 
rate (eGFR) <60 mL/min/1.73 m2 based on the CKD-EPI equation. History of cardiovascular 
disease was assessed based on self-reported history of coronary heart disease (coronary heart 
disease, myocardial infarction, or angina), heart failure, or stroke. We calculated ASCVD risk 
score using the Pooled Cohort Equation among individuals without a history of cardiovascular 
disease aged 40-79.17,18  
 
Descriptive characteristics 
We report descriptive characteristics among whites and Blacks. Among the overall 
population, those with hypertension, and those with uncontrolled hypertension eligible for 
medication initiation or intensification, we estimated the proportion who are female, aged ≥65 
years, with diagnosed diabetes, chronic kidney disease, history of cardiovascular disease, and 
among those without cardiovascular disease, the proportion with an ASCVD risk score ≥10%. 
We compared differences in proportions among whites and Blacks using chi-square tests and 
differences in means using t-tests. We used a 2-sided p-value <0.05 to define statistical 
significance. All analyses incorporated sampling weights to account for the complex survey 




Population attributable fraction and population impact fraction 
 The PAF or PIF is calculated from the prevalence of the exposure and the risk of disease 
associated with the exposure. We considered the exposure as a multi-category variable; we used 
NHANES data to estimate the prevalence of each exposure category and estimates from the 
literature to estimate the risk associated with each exposure category above the reference.8,19  
We used hazard ratios for cardiovascular disease events (coronary heart disease, stroke, 
heart failure, or cardiovascular disease death) associated with SBP above the treatment goal from 
the network meta-analysis by Bundy et al,20 which included 42 antihypertensive clinical trials 
with 144,220 participants. Other studies examining the population impact of treating hypertension 
according to the ACC/AHA guideline recommendations have also used hazard ratios associated 
with SBP above the treatment goal from this network meta-analysis.8,19 We are not aware of a 
similar meta-analysis based on DBP. 
To align with the hazard ratios available for SBP above the treatment goal, we 
categorized SBP values as <130 (reference), 130-134, 135-139, 140-144, 145-149, 150-154, 155-
159, or ≥160 mmHg. We determined treatment eligibility as described earlier, but based only on 
the SBP component. We assumed that only those eligible for pharmacologic treatment would 
have their SBP reduced.  
We used the following formula to calculate the proportion of cardiovascular events 
prevented under each implementation scenario: 
PIF =  
where p is the prevalence in each SBP category and p ′ is the prevalence under the counterfactual, 
HR is the hazard ratio of the exposed compared to the reference level of exposure, and n is the 
total number of SBP categories. The PAF is a specific case of the PIF when the counterfactual 




Hypertension treatment scenarios 
First, we calculated the PAF by race, or the proportion of events which could be 
prevented among whites and Blacks if all individuals eligible for pharmacologic treatment were 
treated and achieved SBP <130 mmHg. We assumed no reduction in SBP occurred among those 
individuals with SBP 130-139 but not eligible for pharmacologic treatment (i.e., recommended 
lifestyle modification only). In a sensitivity analysis, we examined the proportion of events 
prevented if all individuals with systolic blood pressure ≥130 mmHg had their SBP reduced to 
<130 mmHg.  
Second, we estimated the proportion of events prevented in scenarios when less than 
100% of individuals eligible for antihypertensive medication are treated to SBP <130 mmHg. We 
examined the impact of 75%, 50%, 25%, 20%, 15%, 10%, and 5% reductions in uncontrolled 
SBP. We assumed the reduction in uncontrolled SBP occurred uniformly across SBP categories 
(for example, when the overall prevalence of uncontrolled SBP was reduced by 20%, we reduced 
the prevalence in each treatment-eligible SBP category by 20%). We also calculated the absolute 
reduction in uncontrolled SBP and the absolute disparity in uncontrolled SBP for each scenario.  
Among the scenarios with less than complete implementation, we examined the impact of 
a plausible reduction in uncontrolled SBP on preventing cardiovascular events. We highlight 
results for a 20% reduction in uncontrolled SBP as this may be achievable in clinical settings,21 
though there is scarce evidence on real-world improvements in controlling SBP to <130 mmHg. 
Additionally, to understand how different the relative reductions in uncontrolled SBP would have 
to be among whites and Blacks to exacerbate disparities in cardiovascular events, we estimated 
the reduction in uncontrolled hypertension among whites which would prevent the same 
proportion of cardiovascular events as a 20% reduction in uncontrolled hypertension among 
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Blacks. Finally, we considered the impact of reducing uncontrolled SBP by 20% among whites 
and achieving a comparable absolute prevalence of uncontrolled SBP among Blacks (ie, a 
“leveling up” approach).22 
 To estimate the 95% confidence interval for the PAF, we used Monte Carlo simulations 
to account for the uncertainty around the estimated prevalence in each SBP category and 
uncertainty around the hazard ratio. We performed 10,000 repetitions and used the 2.5th and 97.5th 
percentiles to form the confidence interval.8,23 Confidence intervals for the PIF are scaled from 






 Among adults aged 40 years and older, 74.0% of Blacks and 59.9% of whites had 
hypertension (Table 2). In the overall population 56.3% of Blacks and 43.0% of whites had 
uncontrolled hypertension, and 44.4% of Blacks and 31.9% of whites were eligible for 
pharmacologic treatment. The mean SBP (131.5 mmHg vs 125.7 mmHg) and DBP (73.1 mmHg 
vs 71.3 mmHg) were significantly higher among Blacks than whites. The prevalence of diabetes, 
chronic kidney disease, cardiovascular disease and ASCVD risk score ≥10% were significantly 
higher among Blacks than whites. A greater proportion of whites than Blacks were aged 65 and 
older.  
 Among those with hypertension and uncontrolled hypertension, the mean SBP and DBP 
were significantly higher among Blacks than whites. The prevalence of diabetes and ASCVD risk 
score ≥10% were significantly higher among Blacks than whites, but the prevalence of chronic 




Population attributable fraction  
 The prevalence of Black and white adults in each SBP-treatment category is shown in 
Table 3. If all individuals with hypertension eligible for pharmacologic treatment were treated to 
SBP <130 mmHg, 29.0% (27.3%, 30.7%) of cardiovascular events among Blacks and 21.0% 
(19.7%, 22.3%) of cardiovascular events would be prevented (Table 4, Figure 1).  
 If SBP was reduced among all individuals with SBP ≥130 mmHg, regardless of 
recommendation for pharmacologic therapy (i.e., including those for whom only lifestyle 
modification is recommended), we estimated that 30.3% (28.5%, 32.1%) of cardiovascular events 
among Blacks and 22.3% (20.9%, 23.6%) of cardiovascular events among whites would be 
prevented (Supplemental Table 1).  
 
Potential impact fraction 
 For the same proportional reduction in uncontrolled SBP, there would be a greater 
absolute reduction in uncontrolled SBP among Blacks than whites and a reduction in the absolute 
disparity in uncontrolled hypertension (Table 4). Additionally, for a given reduction, the 
proportion of cardiovascular events prevented is higher among Blacks than whites, which would 
reduce relative and absolute disparities in the incidence of cardiovascular events in the 
population.  
For example, a 20% relative reduction in uncontrolled SBP would reduce the prevalence 
of uncontrolled SBP from 30.4% to 24.3% (a 6.1% absolute decrease) among whites and from 
42.5% to 34.0% (an 8.5% absolute decrease) among Blacks, still higher than the baseline 
prevalence of uncontrolled hypertension among whites. The absolute disparity in uncontrolled 
SBP would be reduced from 12.1% to 9.7%. A 20% relative reduction in uncontrolled SBP would 
be expected to prevent 5.8% (5.5%, 6.1%) of all cardiovascular events among Blacks and 4.2% 




Exacerbation of disparities in cardiovascular events 
We found that a 27.6% reduction in uncontrolled hypertension among whites would 
prevent the same proportion of cardiovascular events (5.8%) as a 20% reduction in uncontrolled 
hypertension among Blacks (Figure 1). Therefore, if the reduction in the prevalence of 
uncontrolled SBP is more than ~1.4 times higher (27.6% vs 20%) among whites than Blacks, 
there would be a greater reduction in the proportion of events prevented among whites than 
Blacks, thereby increasing relative and absolute disparities in cardiovascular event rates.  
 
“Leveling up” the prevalence of uncontrolled systolic blood pressure  
A 20% relative reduction in uncontrolled SBP among whites would reduce the prevalence 
of uncontrolled SBP to 24.3%. To achieve a comparable 24.3% prevalence of uncontrolled SBP 
among Blacks would require a 43% relative reduction in uncontrolled SBP (18.2% absolute 
reduction). Reducing the prevalence of uncontrolled SBP to 24.3% among Blacks would be 




We found that nearly three-fourths of Black adults and nearly 60% of white adults aged 
40 years and older had hypertension according to the definition used in the 2017 ACC/AHA 
guideline. Among those with hypertension, a greater proportion of Blacks than whites did not 
have their blood pressure controlled and were eligible for pharmacologic treatment. We found 
that with pharmacologic treatment among those eligible, 29% of cardiovascular events among 
Blacks and 21% of cardiovascular events among whites could be prevented. While this is the 
theoretical maximum, smaller reductions in uncontrolled hypertension could have population 
health benefits and reduce absolute and relative disparities in the incidence of cardiovascular 
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events. However, if guideline-recommended treatment goals are achieved to a greater extent 
among whites than Blacks, it is possible there would be no reduction, or even an exacerbation, of 
existing disparities in cardiovascular events.   
Health systems such as Kaiser Permanente Northern California (KPNC) have shown it is 
possible to substantially improve hypertension control.24 The challenge is to do so in other 
settings and to do so equitably. A study in 12 safety-net clinics in San Francisco which adapted 
the KPNC hypertension program reduced uncontrolled hypertension (defined as <140/90 mmHg) 
among their overall patient population, and achieved 15% to 20% relative reductions in 
uncontrolled hypertension in all racial/ethnic groups, including white, Black, Latino, and Asian 
patients.21 While there was a greater absolute improvement in hypertension control among 
Blacks, disparities were not eliminated; hypertension control was lower among Blacks (66%) 
than whites (75%), Latinos (72%), or Asians (78%) 2 years post-intervention.21 The authors 
conclude targeted strategies are needed to eliminate disparities in hypertension control. 
While we chose to discuss the impact of a 20% relative reduction in uncontrolled 
hypertension, it is unclear what a plausible reduction in uncontrolled hypertension would be using 
a lower blood pressure threshold for control. To achieve SBP <130 mmHg, the average SBP 
reduction needed among those eligible for pharmacotherapy is approximately 15 mmHg among 
whites and Black17 mmHg among Blacks. This means patients would likely require multiple 
drugs,25 coupled with non-pharmacologic lifestyle modifications. Achieving this magnitude of 
SBP reduction in clinical care would likely require intensive follow up, and the uptake and 
efficacy of interventions is often socially patterned.26 We showed that even a 1.4-fold difference 
in the reduction in uncontrolled hypertension among whites versus Blacks would not reduce or 
exacerbate disparities in cardiovascular events. Again, the challenge is to mitigate inconsistencies 




Even if the guideline target of SBP <130 mmHg is not achieved in clinical care, a small 
shift in the distribution of blood pressure in the population can have large cardiovascular health 
benefits.27 Our findings also highlight the importance of equity-promoting policy and 
environmental changes to reduce blood pressure in the population,26,28 such as sodium reduction 
in the food supply, increasing access to supermarkets and healthy foods, and increasing access to 
safe spaces for physical activity, which decrease reliance on individual behavior change (by 
physicians, patients, caregivers/families) and may be necessary to achieve the desired magnitude 
of blood pressure reduction.6,29 In addition to changing the context for health, achieving 
cardiovascular health equity will require us to directly address the root causes of racial 
inequalities in health. Specifically, it is necessary to address systemic racism in the U.S. as a 
fundamental cause of inequalities in socioeconomic resources and health outcomes.30  
 Our study has several limitations. First, we assume that the hazard ratios are the same 
among Blacks and whites. However, for the same SBP, the risk of stroke for example, is higher 
among Blacks than whites.6 Second, we are unable to estimate the uncertainty for the relative and 
absolute differences in uncontrolled SBP under these scenarios. We algebraically estimated the 
proportion of individuals in each SBP category under the counterfactual and thus do not have 
confidence intervals for the prevalence. Additionally, we assumed reductions in uncontrolled SBP 
occurred uniformly across categories which may not occur. Third, due to limited sample sizes, we 
did not examine the PAF or PIF among population subgroups within racial groups or among other 
racial/ethnic subgroups. Fourth, we did not consider the risks of adverse events, though the 
benefits of lowering blood pressure to a more stringent target outweigh the risks at the population 
level.8 Our study also has several strengths. We used a similar method as two previous studies of 
the potential impact of the 2017 ACC/AHA guideline to estimate the PAF.8,19 Though we used a 
different method than Clark et al, who estimated hazard ratios for hypertension based on analyses 
of the Jackson Heart Study and the Reasons for Geographic and Racial Differences in Stroke 
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(REGARDS) studies, our estimates for the PAF among Blacks are similar.14 Our work extends 
previous studies by considering the implications for racial disparities in uncontrolled 
hypertension and cardiovascular disease events. We also consider scenarios when less than 
complete implementation occurs.  
 
Conclusion  
Recently, the American Heart Association announced its 2030 High Impact Goal to 
equitably increase healthy life expectancy in the population.31 Improving primordial prevention 
and treatment of  hypertension can play a major role in achieving this goal. Reducing blood 
pressure to the ACC/AHA guideline-recommended target of <130/80 mmHg would 
disproportionately benefit populations with higher blood pressures who are at increased risk of 
cardiovascular disease events and deaths, including African Americans. Efforts are warranted to 







Table 1. Blood pressure thresholds used in 2017 ACC/AHA guideline to define 
hypertension, recommend pharmacologic treatment initiation, and pharmacologic 
treatment goals. 
Criteria Population  Blood pressure 
threshold 
Hypertension definition  
Systolic blood pressure All adults ≥130 mmHg 
Diastolic blood pressure All adults  ≥80 mmHg 
Pharmacologic treatment initiation 
Systolic blood pressure   
 General population ≥140 mmHg 
 Diabetes or chronic kidney disease ≥130 mmHg 
 History of cardiovascular disease or 
ASCVD risk ≥10% 
≥130 mmHg 
 Aged ≥65 years ≥130 mmHg 
Diastolic blood pressure   
 General population ≥90 mmHg 
 Diabetes or chronic kidney disease ≥80 mmHg 
 History of cardiovascular disease or 
ASCVD risk ≥10% 
≥80 mmHg 
Pharmacologic treatment goal 
Systolic blood pressure   
 General population <130 mmHg 
 Diabetes or chronic kidney disease <130 mmHg 
 History of cardiovascular disease or 
ASCVD risk ≥10% 
<130 mmHg 
 Aged ≥65 years <130 mmHg 
Diastolic blood pressure   
 General population <90 mmHg 
 Diabetes or chronic kidney disease <80 mmHg 
 History of cardiovascular disease or 
ASCVD risk ≥10% 
<80 mmHg 
ASCVD = Atherosclerotic cardiovascular disease. 10-year ASCVD risk calculated using race-sex 








Table 3. Systolic blood pressure category and eligibility for pharmacologic treatment 
overall and among those with hypertension, by race – NHANES 2011-2016. 
  Overall  Hypertension 











<130 Not eligible 64.7 (0.9) 51.2 (1.2) 34.3 (1.6) 30.1 (1.5) 
130-139, not high risk Not eligible 4.9 (0.5) 6.3 (0.6) 9.1 (0.9) 9.0 (0.9) 
130-134, high risk or on treatment Eligible 6.5 (0.4) 8.2 (0.5) 12.2 (0.9) 11.8 (0.8) 
135-139, high risk or on treatment Eligible 5.2 (0.4) 6.2 (0.5) 9.6 (0.8) 8.9 (0.7) 
140-144 Eligible 5.8 (0.5) 6.9 (0.5) 10.9 (0.9) 9.9 (0.9) 
145-149 Eligible 3.9 (0.3) 5.0 (0.5) 7.3 (6.3) 7.1 (0.7) 
150-154 Eligible 3.0 (0.4) 4.6 (0.6) 5.5 (0.8) 6.5 (0.7) 
155-159 Eligible 1.8 (0.2) 3.5 (0.5) 3.3 (0.4) 5.0 (0.7) 
≥160 Eligible 4.2 (0.4) 8.1 (0.6) 7.9 (0.8) 11.6 (0.8) 
Total SBP ≥130 eligible for 
pharmacologic treatment Eligible 30.4 (0.9) 42.5 (1.2) 56.6 (1.6) 60.9 (1.5) 
High risk includes those individuals who are aged ≥65 years, have diabetes, chronic kidney 
disease, or 10-year ASCVD risk ≥10%. Those with systolic blood pressure 130-139 mmHg who 




Table 4. Proportion of cardiovascular events prevented with reductions in uncontrolled 
systolic blood pressure and disparities in uncontrolled systolic blood pressure.  
Relative reduction 
in uncontrolled SBP  
% uncontrolled 
SBP 
Absolute disparity in 
% uncontrolled SBP 
% CVD events 
prevented 
White Black (ref white) White Black 
0% reduction 30.4 42.5 12.1 – 
 
– 
































The reduction in uncontrolled systolic blood pressure (SBP) is applied to the categories of 
individuals with SBP ≥130 mmHg and eligible for pharmacologic treatment.  
 
A 100% reduction in uncontrolled SBP corresponds to the population attributable fraction (PAF). 
We estimated 95% confidence intervals for the PAF using the centile method. The 95% 
confidence intervals for lesser implementation scenarios are scaled from those for the PAF. 
 
In lesser implementation scenarios, we moved the relevant percentage of individuals from each 
SBP category to the reference group (<130 mmHg). For example, when there was a 20% 
reduction in uncontrolled SBP, we moved 20% of individuals in each SBP category eligible for 
treatment to the reference group. This was done algebraically and therefore, we do not present 







Figure 1. Relative reduction in prevalence of uncontrolled systolic blood pressure and 















A 100% reduction in uncontrolled SBP corresponds to the population attributable fraction (PAF). 
A 100% reduction, or elimination, of uncontrolled SBP would prevent 29.0% (27.3%, 30.7%) of 
cardiovascular events among Blacks and 21.0% (19.7%, 22.3%) of cardiovascular events among 
whites.  
The solid lines on the figure illustrate a 20% relative reduction in the prevalence of uncontrolled 
SBP among Blacks and whites. A 20% relative reduction in the prevalence of uncontrolled SBP is 
expected to prevent 5.8% (5.5%, 6.1%) and 4.2% (3.9%, 4.5%) of cardiovascular events among 
Blacks and whites, respectively.  
The dashed lines on the figure show that to prevent 5.8% of cardiovascular events among whites 
would require a 27.6% relative reduction in the prevalence of uncontrolled SBP. If the percent 
reduction in uncontrolled SBP is >1.4 times higher among whites than Blacks (27.6% vs 20%), 





Figure 2. Prevalence of uncontrolled systolic blood pressure and proportion of 
cardiovascular events prevented at baseline.  
 
A 20% relative reduction in uncontrolled SBP among whites would reduce the prevalence of 
uncontrolled SBP to 24.3%, which would prevent 4.2% (3.9%, 4.5%) of cardiovascular events 
among whites. Reducing the prevalence of uncontrolled SBP to 24.3% among Blacks (i.e., 










 This dissertation examined key issues related to addressing disparities in hypertension 
management in the U.S. Hypertension is a leading modifiable risk factor for cardiovascular 
disease and contributes to cardiovascular health disparities in the population. Our work is timely 
given the focus on health equity in the American Heart Association’s 2030 goals.1 The results of 
our epidemiologic investigations can inform public health action and future research priorities.  
 
Summary of Findings and Implications 
 In Chapter 1, we presented trends from 1999 to 2016 in hypertension prevalence, 
awareness, treatment, and control by age, sex, and race/ethnicity based on data from the National 
Health and Nutrition Examination Survey.2 We observed increases in hypertension awareness, 
treatment, and control among all age groups. However, increases occurred primarily between 
1999 and 2010, with few changes after. Hypertension control was lower for Blacks than whites of 
all ages, and awareness, treatment, and control were lower among younger Hispanics as 
compared to whites.  
Given that the proportion of adults with hypertension who have their BP controlled has 
not increased since 2010, it was instructive to examine barriers to hypertension control by 
population subgroup. Our findings highlight that targeted efforts are needed to improve treatment 
to control among Blacks and address gaps at all stages among younger Hispanics. 
In Chapter 2, we used data from a nationally representative audit of physician office 
visits to quantify the extent of terminal digit preference in office BP measurements among adults 
with treated hypertension. To our knowledge, this is the first study to examine terminal digit 
preference nationally in the U.S. and to report trends over time. We found that the proportion of 
BP measurements with a terminal digit zero was much greater (~40%) than expected by chance 
alone (~10-20%). Despite a modest decrease from 2014 to 2018 in the percent of visits with 
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systolic (43.0% to 38.1%) or diastolic (44.3% to 39.4%) blood pressure recordings ending in 
zero, terminal digit preference remains a common source of BP measurement error.  
Terminal digit preference was higher and there was less reduction among visits where 
treatment was first initiated (vs subsequent treatment visits) and at visits to cardiologists (vs 
primary care physicians). Terminal digit preference was reduced around thresholds for 
hypertension control, but it is unclear whether this reflects more accurate measurement when it 
may affect treatment decisions or a preference for BP values just below certain thresholds which 
may have adverse consequences for patients.3 There was little change in the proportion of 
measurements ending in 1, 3, 7, or 9, which we would expect to increase with increasing use of 
automated BP devices. This may suggest continued use of manual devices even when automated 
devices are present or errors in recording, such as intentional rounding of measurements.  
Blood pressure measurement error contributes to both under- and overtreatment of 
individuals with hypertension. It is feasible to reduce terminal digit preference through the use of 
automated devices, clinical training, and support.4 Reducing terminal digit preference, which is 
pervasive in practice, is potentially low-hanging fruit for improving the accuracy of BP 
measurement and may drive other improvements in clinical management of hypertension.   
Chapter 3 examined changes in hypertension control among Black and white older adults 
with treated hypertension in the Atherosclerosis Risk in Communities (ARIC) Study before and 
after the publication of a new hypertension guideline in 2014. The 2014 hypertension guideline 
raised BP treatment goals from <140/90 mmHg in the general population and <130/80 among 
those with diabetes or chronic kidney disease to <150/90 mmHg among adults aged ≥60 years 
without diabetes or chronic kidney disease, and to <140/90 mmHg for those with diabetes or 
chronic kidney disease; the 2014 guideline retained the target of <140/90 mmHg for adults <60 
years of age without comorbidities.  
We found that a greater proportion of white than Black adults had systolic blood pressure 
(SBP) <140 mmHg 2011-2013 (75.4% vs 66.0%), while a similar proportion of whites and 
88 
 
Blacks had SBP <140 mmHg in 2016-2017 (59.4% vs 56.5%). There were no differences in the 
prevalence of SBP <140 mmHg by diabetes status or chronic kidney disease among whites or 
Blacks at baseline. One-third of both whites and Blacks with SBP <140 at baseline had SBP ≥140 
mmHg at follow up. Among those controlled at baseline, reduced kidney function was associated 
with uncontrolled SBP at follow up among whites [odds ratio (OR): 1.32; 95% confidence 
interval (CI): 1.00, 1.75] and among Blacks (OR: 1.47; 95% CI: 0.92, 2.35); though not 
statistically significant among Blacks, we focus on the magnitude of association. We also found 
that Blacks with diabetes who had controlled SBP at follow up were more likely than those 
without to have uncontrolled SBP at follow up (OR: 1.92; 95% CI: 1.27, 2.92), and that the 
association with diabetes among Blacks was significantly different than among whites (P for 
interaction = 0.009). Among those with uncontrolled SBP at baseline, ~40% of whites and Blacks 
were controlled at follow up. Blacks with reduced with reduced kidney function (OR: 0.44, 95% 
CI: 0.22, 0.87) had lower odds of control and there was a significant interaction by race (P for 
interaction = 0.004). 
The 2014 hypertension guideline was controversial in its decision to raise hypertension 
treatment thresholds. Few studies have examined changes in hypertension control before and after 
this guideline was published.5,6 Two previous studies showed no changes in control to BP 
<140/90 mmHg or mean BP from one year before to one year after the guideline, but are limited 
to single health care systems which may not capture variability in care practices, include mostly 
white patients, and one of the studies did not include patients with diabetes or chronic kidney 
disease.5,6 Our work added to the literature by including Black and white adults from multiple 
geographic locations with well-characterized information on their health status, and examines 
hypertension control 2-3 years before and after the guideline publication which may allow us to 
capture changes in clinical practice in response to guideline changes. While we found that 
changes hypertension control overall were similar by race, we found that Blacks with diabetes or 
reduced kidney function were less likely to have hypertension control at follow up. Higher 
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treatment goals recommended in 2014 for older adults and those with diabetes and chronic kidney 
disease may have contributed to these findings and unintended differences by race.  
Finally, in Chapter 4, we examined the potential impact on cardiovascular disease events 
of treating individuals with hypertension to a lower BP goal of <130/80 recommended by the 
American College of Cardiology (ACC) and American Heart Association (AHA) in 2017. We 
calculated the proportion of all cardiovascular disease events which could be prevented among 
Black and white adults aged ≥40 if all those eligible for pharmacologic treatment were treated to 
the ACC/AHA guideline-recommended goal. We estimated that 29.0% (95% CI: 27.3%, 30.7%) 
of cardiovascular events among Blacks and 21.0% (95% CI: 19.7, 22.3%) of cardiovascular 
events among whites could be prevented, which would reduce relative and absolute racial 
disparities in cardiovascular events in the population. Even in if less than 100% of individuals 
eligible for pharmacologic therapy were treated to the goal, with the same relative reduction in 
uncontrolled hypertension, the proportion of cardiovascular events prevented is higher among 
Blacks than whites. However, if the relative reduction in uncontrolled hypertension is more than 
~1.4 times higher among whites than Blacks, there would be a greater reduction in the proportion 
of events prevented among whites than Blacks, thereby exacerbating disparities.  
Treating hypertension to the 2017 ACC/AHA goal could reduce absolute and relative 
racial disparities in cardiovascular events in the population, but there are challenges with respect 
to implementation and ensuring equitable improvements in hypertension control occur in practice. 
For example, the magnitude of BP reduction required to reach the goal of <130/80 mmHg among 
those eligible for new or additional antihypertensive treatment is large (~15 mmHg among whites 
and ~17 mmHg among Blacks), thus treatment to a lower goal will likely require intensive efforts 
to engage patients and address barriers to hypertension control which exist at multiple levels.7,8 
Additionally, though the benefits in terms of prevention of cardiovascular disease events would 
be greater among Blacks than whites for a comparable relative reduction in uncontrolled 
hypertension, our goal should be to eliminate absolute disparities in uncontrolled hypertension. 
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Some health systems have shown it is possible to achieve similar relative reductions in 
uncontrolled hypertension among racial/ethnic groups, but targeted approaches are likely needed 




Blood pressure measurement  
 To identify and address the determinants of terminal digit preference, it would be useful 
to conduct research to understand the types of BP devices currently used in practice for screening 
and diagnosis of hypertension, and to monitor the response to hypertension treatment.10 We 
believe the use of automated BP devices has increased in clinical practice, but our results suggest 
BP may still be measured with manual devices and/or that BP measurements from automated 
devices are rounded to zero; it is important to understand the source of error to design appropriate 
interventions.  
The 2017 ACC/AHA guideline states that there is growing evidence to support the use of 
automated office BP measurements, but stops short of recommending the use of automated BP 
devices in office settings as Canadian hypertension guidelines explicitly recommend.11,12 Future 
U.S. guidelines could more strongly recommend the use of automated BP devices in clinical care. 
Regardless of the type of BP device used, accurate BP measurement is critical to patient 
care. Implementation research is needed to better incorporate recommended BP measurement 
procedures, which may not always be practical in the current clinical environment.  
 
Guideline-recommended treatment  
 The results from chapters 3 and 4 of this dissertation highlight the potential positive 
impact on cardiovascular health in the population and disparities in cardiovascular health 
associated with implementing current recommended hypertension treatment goals, but also the 
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potential to widen disparities if recommendations are applied inconsistently across population 
subgroups. Inconsistent application could occur as a result of controversy or confusion regarding 
available hypertension guidelines from leading professional societies in the U.S.  
 One area for future research is to understand at the health system and physician level 
what treatment targets are being used in clinical practice. However, it is also well-documented 
that physicians do not always adhere to guidelines.13 Factors may include lack of agreement with 
guideline recommendations, inertia to treat based on previous higher BP targets, “lack of outcome 
expectancy,” and others.13,14 The Institute of Medicine has previously recommended research to 
understand why physicians do not adhere to hypertension guidelines.15  Increasing understanding 
the factors which influence decision-making among physicians and patients about hypertension 
treatment would be a major contribution to the field, but to our knowledge, this research 
recommended in 2010 has not been funded and should be prioritized. 
 Another area of for future study is implementation research regarding the use of 
guideline-driven hypertension treatment protocols in clinical care. Protocols help standardize 
clinical care and may help to ensure patients from different racial/ethnic groups or by 
socioeconomic status are treated consistent with current guidelines. It is unknown how widely 
adopted protocols are in clinical care in the U.S. Further, given more intensive treatment will be 
needed to achieve the lower target recommended by the 2017 ACC/AHA guideline, protocols 
aimed at achieving this goal should be evaluated in diverse care settings and effective practices 
should be disseminated and scaled up.  
 Lastly, future guideline committees, which  could include an explicit consideration for 
how clinical practice guidelines address issues of equity.16,17 Guideline committees can consider 
equity when formulating research questions.17 Additionally, guideline committees can address 
key questions about their recommendations such as the value of the interventions to different 
subgroups, the expected effects among population subgroups, how to minimize barriers to 
implementation among disadvantaged groups, and ensuring plans to evaluate the impact of the 
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guideline recommendations include monitoring its effect by subgroup.16,18 Guideline committees 
should also include diverse representation and seek feedback from members of disadvantaged 
groups during guideline development.17  
 
Addressing the social determinants of health  
 Though this dissertation focuses on hypertension treatment, it will not be possible to treat 
our way to health equity in the U.S. First, addressing the social determinants of health to prevent 
hypertension is necessary to achieving equity. Second, health care occurs in the context of the 
social determinants of health.8 Public health and health care interventions will not be optimally 
effective unless we address the fundamental causes of racial health disparities, which are 
inequalities in socioeconomic resources resulting from historical, social, and political 
injustices.19–21 Factors such as  institutional and interpersonal racism, access and affordability of 
care, neighborhood conditions and residential segregation, are associated with blood pressure 
levels and may also have independent effects on health outcomes. 21,22 Further, the place-based 
historical legacy of slavery is associated with smaller decreases in heart disease mortality among 
U.S. Blacks, even after controlling for potential mediators.23  
When designing interventions in the health care setting, approaching clinical care in the 
framework of the socioecological model may help to develop targeted interventions which 
address barriers to hypertension control among population subgroups.8 Multilevel interventions 
may be uniquely effective for addressing health disparities and the National Institutes of Health 
has invested in such approaches.24–26 The Patient Centered Outcomes Research Institute (PCORI) 
has also specifically funded studies multilevel interventions to reduce disparities in hypertension 
control, which are ongoing.27,28 However, there is much more work to be done to advance 





 This dissertation contributes to our knowledge of disparities in hypertension control in 
the U.S. and the implications of recent hypertension guidelines for patient outcomes, population 
health, and health disparities. Further research can help understand factors which influence BP 
measurement and treatment, and inform interventions to improve hypertension control and 
eliminate disparities. Eliminating disparities in hypertension control is a priority for 
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Web Table 1. Hypertension Prevalence, Awareness, Treatment, Control and Control 
Among Those Treated – US adults aged ≥25, National Health and Nutrition Examination 
Survey 1999–2016. 
  
1999–2004 2005–2010 2011–2016 
Hypertension prevalence, % (SE) 
 25–44  11.8 (0.7) 12.0 (0.6) 12.8 (0.7) 
 45–64 39.5 (1.3) 39.7 (1.1) 40.7 (0.9) 
 ≥65 70.6 (1.0) 70.2 (1.1) 67.6 (1.3) 
Hypertension awareness, % (SE) 
 25–44  62.5 (3.1) 66.7 (2.6) 74.3 (2.0)*,† 
 45–64 74.1 (1.6) 81.8 (1.0)* 83.2 (1.1)* 
 ≥65 74.0 (1.1) 83.7 (1.0)* 86.7 (0.9)*,† 
Hypertension treatment, % (SE) 
 25–44  46.1 (3.4) 51.2 (2.7) 56.6 (2.3)* 
 45–64 62.8 (1.7) 73.1 (1.2)* 74.6 (1.5)* 
 ≥65 67.1 (1.6) 79.9 (0.9)* 82.1 (1.1)* 
Hypertension control, % (SE) 
 25–44  33.5 (3.0) 38.6 (2.6) 44.6 (2.3)* 
 45–64 39.3 (1.7) 51.7 (1.4)* 55.7 (1.9)* 
 ≥65 31.7 (1.3) 49.3 (1.1)* 49.9 (1.6)* 
Hypertension control among treated, % (SE) 
 25–44  72.7 (3.2) 75.3 (2.4) 78.8 (2.2) 
 45–64 62.6 (1.5) 70.7 (1.4)* 74.6 (1.5)* 
 ≥65 47.2 (1.5) 61.7 (1.1)* 60.8 (1.6)* 
 
*Statistically significant difference (P<0.05) as compared to 1999–2004. 







Web Table 3. Hypertension Prevalence, Awareness, Treatment, Control and Control 
Among Those Treated by Age Group and Sex – US adults aged ≥25, National Health and 
Nutrition Examination Survey 1999–2016. 
 
      Estimate, % (SE) Difference (Women vs Men), % (SE) 
  
  
1999–2004 2005–2010 2011–2016 1999–2004 2005–2010 2011–2016 
Prevalence     
  25–44 Men  14.3 (1.1) 14.9 (0.8) 14.1 (1.1)   
 
  
    Women 9.1 (0.7) 8.9 (0.6) 11.4 (0.8)*,† -5.2 (1.3)‡ -6.1 (0.8)‡ -2.7 (1.2)‡,‖ 
  45–64 Men  38.5 (1.8) 39.5 (1.3) 43.3 (1.4)*,†   
 
  
    Women 40.5 (1.5) 39.9 (1.5) 38.2 (1.2) 2.0 (1.9) 0.5 (1.8) -5.1 (1.8)‡,§,‖ 





Women 76.5 (1.1) 73.7 (1.3) 70.6 (1.4) 13.8 (2.0) 8.1 (2.1)‡,§ 7.0 (1.8)‡,§ 
Awareness            
  25–44 Men  57.8 (3.3) 58.0 (3.2) 66.4 (2.9)   
 
  
    Women 70.8 (4.1) 81.9 (3.5)* 84.5 (2.0)* 13.0 (4.4)‡ 23.9 (4.3)‡ 18.1 (3.2)‡ 
  45–64 Men  72.6 (2.1) 78.8 (1.4)* 81.0 (1.5)*   
 
  
    Women 75.4 (2.6) 84.7 (1.3)* 85.5 (1.7)* 2.8 (3.6) 5.8 (1.9)‡ 4.5 (2.3) 





Women 73.6 (1.5) 83.5 (1.3)* 87.4 (1.1)*,† -1.0 (2.2) -0.6 (1.7) 1.5 (1.6) 
Treatment             
  25–44 Men  40.0 (3.9) 41.5 (3.3) 45.3 (3.3)   
 
  
    Women 57.0 (4.3) 68.3 (4.0) 71.2 (2.8)* 17.0 (5.3)‡ 26.8 (4.9)‡ 25.8 (4.0)‡ 
  45–64 Men  61.0 (1.9) 69.1 (1.5)* 70.1 (1.9)*   
 
  
    Women 64.4 (2.6) 76.9 (1.6)* 79.4 (1.9)* 3.5 (2.9) 7.8 (1.9)‡ 9.3 (2.5)‡ 





Women 66.4 (2.1) 79.9 (1.2)* 83.0 (1.4)* -1.9 (2.4) -0.1 (1.8) 2.0 (1.7) 
Control                
  25–44 Men  27.7 (3.7) 29.4 (2.9) 32.0 (2.7)   
 
  
    Women 43.8 (4.4) 54.8 (4.5) 61.0 (2.9)* 16.2 (5.8)‡ 25.4 (5.2)‡ 29.0 (2.9)‡ 
  45–64 Men  39.7 (2.4) 48.2 (2.0)* 50.2 (2.5)*   
 
  
    Women 39.0 (2.1) 55.1 (1.8)* 61.5 (2.1)*,† -0.7 (3.0) 6.8 (2.5)‡ 11.3 (2.7)‡,§ 





Women 27.3 (1.5) 46.5 (1.2)* 46.2 (2.0)* -11.3 (2.2)‡ -7.0 (1.7)‡ -8.9 (2.4)‡ 
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Control among treated           
  25–44 Men  69.2 (5.3) 70.8 (3.5) 70.5 (3.9)   
 
  
    Women 77.0 (4.1) 80.1 (3.4) 85.7 (2.3) 7.7 (7.3) 9.3 (5.1) 15.2 (4.5) 
  45–64 Men  65.1 (3.0) 69.8 (2.2) 71.7 (2.2)*   
 
  
    Women 60.5 (1.8) 71.6 (1.6) 77.5 (2.0)*,† -4.6 (3.8) 1.8 (2.7) 5.8 (2.9)‡,§ 
  ≥65 Men  56.6 (2.1) 66.8 (1.5)* 68.1 (1.9)*   
 
  
    Women 41.2 (1.8) 58.1 (1.3)* 55.7 (2.0)* -15.4 (2.7)‡ -8.7 (1.8)‡,§ -12.4 (2.4)‡ 
 
*Statistically significant difference (P<0.05) as compared to 1999–2004 within category of age 
and sex. 
†Statistically significant difference (P<0.05) as compared to 2005–2010 within category of age 
and sex. 
‡Statistically significant difference (P<0.05) within survey cycle for women versus men.  
§Statistically significant change in difference (P<0.05) as compared to 1999–2004 (ie, 
interaction). 





Web Table 4. Hypertension Prevalence, Awareness, Treatment, Control and Control 
Among Those Treated by Age Group and Race/Ethnicity – US Adults Aged ≥25, National 
Health and Nutrition Examination Survey 1999–2016. 
 
      Estimate, % (SE) Difference (Reference White), % (SE) 
  
  
1999–2004 2005–2010 2011–2016 1999–2004 2005–2010 2011–2016 
Prevalence         





Black 20.3 (1.5) 20.0 (1.3) 22.3 (1.3) 9.6 (1.7)‡ 8.2 (1.7)‡ 10.0 (1.4)‡ 
  
 
Hispanic 9.4 (1.0) 7.9 (0.9) 12.0 (1.1)† -1.3 (1.2) -3.8 (1.2)‡ -0.2 (1.4) 
  45–64 White 37.6 (1.6) 37.5 (1.3) 38.7 (1.3)       
  
 
Black 57.2 (1.9) 58.9 (2.1) 60.0 (1.6) 19.6 (2.5)‡ 21.4 (2.4)‡ 21.3 (2.1)‡ 
    Hispanic 35.2 (2.0) 35.3 (2.0) 35.0 (2.6) -2.4 (2.7) -2.2 (2.3) -3.7 (2.8) 
  ≥65 White 69.4 (1.2) 69.0 (1.3) 65.7 (1.5)       
  
 
Black 81.9 (2.2) 83.5 (1.4) 80.7 (1.5) 12.5 (2.4)‡ 14.5 (1.8)‡ 15.0 (1.9)‡ 
  
 
Hispanic 69.1 (2.1) 67.7 (2.5) 68.5 (2.8) -0.3 (2.5) -1.3 (2.7) 2.8 (2.8) 
Awareness             





Black 62.4 (4.3) 71.2 (3.7) 79.2 (2.5)* -4.1 (5.9) 3.6 (4.4) 3.8 (4.9) 
  
 
Hispanic 44.4 (5.9) 46.4 (6.0) 65.6 (4.4)*,† -22.1 (7.6)‡ -21.2 (6.3)‡ -9.8 (6.3) 
  45–64 White 72.9 (2.0) 82.0 (1.3)* 83.6 (1.6)*       
  
 
Black 81.4 (1.6) 84.9 (1.5) 85.5 (1.5) 8.5 (2.3)‡ 2.9 (1.9) 1.9 (2.2)§ 
    Hispanic 70.7 (3.8) 75.6 (2.0) 78.6 (2.8) -2.2 (4.3) -6.4 (2.3)‡ -5.0 (3.3) 
  ≥65 White 73.5 (1.2) 83.1 (1.1)* 87.2 (1.2)*,†       
  
 
Black 80.6 (1.9) 90.4 (1.7)* 89.1 (1.0)* 7.2 (2.0)‡ 7.4 (2.1)‡ 1.9 (1.5)§,‖ 
  
 
Hispanic 69.7 (2.2) 77.5 (4.2) 83.7 (2.4)* -3.8 (2.5) -5.5 (4.3) -3.5 (2.6) 
Treatment             





Black 45.9 (4.2) 58.7 (4.1)* 57.9 (3.2)* -3.1 (5.7) 6.3 (4.9) -2.0 (4.6) 
  
 
Hispanic 24.0 (5.2) 29.0 (4.8) 45.0 (4.7)*,† -25.0 (6.1)‡ -23.4 (6.2)‡ -15.0 (5.7)‡ 
  45–64 White 62.3 (1.9) 73.9 (1.7)* 75.3 (2.2)*       
  
 
Black 70.4 (2.1) 74.4 (1.9) 77.8 (1.9)* 8.0 (2.6)‡ 0.5 (2.6)§ 2.5 (3.0) 
    Hispanic 56.6 (4.9) 67.4 (2.5) 70.9 (3.0)* -5.7 (5.0) -6.5 (2.7)‡ -4.4 (3.8) 
  ≥65 White 66.5 (1.6) 79.5 (1.1)* 82.4 (1.4)*       
  
 





Hispanic 62.5 (1.7) 71.3 (4.5) 79.3 (2.4)* -4.0 (2.1) -8.1 (4.6) -3.2 (2.9) 
Control                





Black 24.9 (2.8) 35.6 (3.6)* 38.1 (3.4)* -14.0 (4.7)‡ -6.5 (4.6) -12.3 (4.6)‡ 
  
 
Hispanic 15.6 (3.7) 16.8 (3.9) 35.1 (4.3)*,† -23.3 (5.1)‡ -25.3 (5.6)‡ -15.2 (4.9)‡ 
  45–64 White 41.6 (2.0) 54.6 (1.8)* 58.4 (2.8)*       
  
 
Black 38.0 (2.0) 45.8 (2.1)* 50.9 (2.2)* -3.6 (2.7)‡ -8.8 (2.6)‡ -7.6 (3.7)‡ 
    Hispanic 30.8 (4.3) 46.1 (2.1)* 50.0 (3.9)* -10.7 (4.3)‡ -8.5 (2.7)‡ -8.5 (5.0) 
  ≥65 White 32.2 (1.4) 50.0 (1.3)* 51.3 (2.0)*       
  
 
Black 31.9 (2.2) 49.9 (2.7)* 45.9 (1.9)* -0.3 (2.7) -0.1 (3.1) -5.3 (2.4)‡ 
  
 
Hispanic 25.5 (2.3) 34.8 (3.2)* 46.0 (3.6)*,† -6.7 (2.6)‡ -15.2 (3.4)‡,§ -5.2 (4.2) 
Control among treated           





Black 54.3 (4.9) 60.6 (5.5) 65.8 (4.2) -25.0 (6.3)‡ -19.7 (7.0)‡ -18.2 (5.2)‡ 
  
 
Hispanic 65.1 (7.9) 57.9 (10.0) 78.2 (5.9) -14.2 (9.2) ‡ -22.4 (11.0)‡ -5.8 (6.5) 
  45–64 White 66.7 (2.0) 73.9 (1.4)* 77.7 (2.1)*       
  
 
Black 54.0 (2.4) 61.5 (2.3)* 65.4 (1.8)* -12.7 (3.1)‡ -12.4 (2.6)‡ -12.3 (2.7)‡ 
  
 
Hispanic 54.4 (4.4) 68.4 (2.6)* 70.6 (3.5)* -12.3 (4.5)‡ -5.5 (2.8) -7.1 (4.1) 
  ≥65 White 48.4 (1.7) 62.9 (1.2)* 62.2 (1.9)*       
  
 
Black 42.0 (2.6) 57.4 (3.1)* 53.8 (2.2)* -6.4 (3.1)‡ -5.4 (3.3) -8.3 (2.5)‡ 
    Hispanic 40.8 (3.6) 48.7 (3.2)* 58.0 (3.6)* -7.6 (4.1) -14.2 (3.6)‡ -4.1 (4.1) 
 
*Statistically significant difference (P<0.05) as compared to 1999–2004 within category of age 
and race/ethnicity. 
†Statistically significant difference (P<0.05) as compared to 2005–2010 within category of age 
and race/ethnicity. 
‡Statistically significant difference (P<0.05) within survey cycle for blacks or Hispanics as 
compared to whites.  
§Statistically significant change in difference (P<0.05) as compared to 1999–2004 (ie, 
interaction). 











Web Table 7. Hypertension Treatment Goals from Major National Guidelines During 
1999–2016.   
 
Dates Guideline Blood Pressure Goals 
1999–2003  JNC6* <140/90 mmHg for all patients – lower if tolerated 
2003–2014 JNC7 <130/80 mmHg for those with diabetes or chronic kidney disease  
<140/90 for all other patients 
2014–2016 JNC8 Panel 
Member 
Report  
<150/90 mmHg for adults aged ≥60 years without diabetes or 
chronic kidney disease  
<140/90 for all other patients 
 
JNC = Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High 
Blood Pressure. 





Appendix for Chapter 2  
 
 
Supplemental Table. Proportion of systolic and diastolic blood pressure measurements 
above and below guideline-recommended treatment goals – Hypertension treatment visits, 
2014–2018.  
 2014 2015 2016 2017 2018 
Systolic blood pressure (mmHg) 
128-129 4.1 4.8 4.3 3.9 4.1 
131-132 3.9 4.3 4.2 4.1 4.5 
      
138-139 4.3 4.3 4.4 4.8 4.8 
141-142 2.8 2.9 2.7 3.1 3.0 
      
148-149 2.2 2.0 2.4 1.8 2.1 
151-152 1.1 1.3 1.0 1.2 1.4 
      
Diastolic blood pressure (mmHg) 
78-79 5.6 6.0 6.1 7.0 6.4 
81-82 6.0 5.8 6.1 5.5 6.1 
      
88-89 3.9 4.4 4.5 5.2 5.7 
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Supplemental Table 1. Characteristics of older adults with treated hypertension in  
2011–2013 present and absent at 2016–2017 study visit.  
 
 
Present at  
2016-2017 Exam 
Missing at  
2016-2017 Exam p-value 
N (%) 2250 (60%) 1502 (40%)  
Age, mean years (SD) 74.8 (4.7) 76.9 (5.4) <0.001 
Female sex 59.3% 57.7% 0.32 
Black race 28.9% 25.6% 0.029 
Education     
Less than high school  13.3% 18.4% <0.001 
High school or vocational school 41.7% 44.0%  
College or higher 44.9% 37.5%  
Poor physical function  88.3% 76.6% <0.001 
Pre-frail or frail  51.3% 65.6% <0.001 
Mild cognitive impairment or 
dementia 18.7% 32.6% <0.001 
Depressive symptoms 6.4% 6.9% 0.54 
Medication adherence    
High 59.7% 59.9% 0.92 
Intermediate 38.0% 38.1%  
Low 2.3% 2.1%  
Hypertension duration, mean years 
(SD) 17.2 (7.2) 18.6 (6.7) <0.001 
BMI category, kg/m2    
<25 17.7% 23.8% <0.001 
25-<30 40.0% 39.1%  
≥30 42.3% 37.1%  
Diabetes 32.1% 40.1% <0.001 
eGFR <60 mL/min/1.73 m2 28.6% 39.7% <0.001 
Prevalent coronary heart disease 16.1% 20.7% <0.001 
Prevalent stroke 3.7% 4.9% 0.091 
Prevalent heart failure 13.5% 21.0% <0.001 
SD = Standard Deviation. eGFR = Estimated Glomerular Filtration Rate. BMI = Body Mass 




Supplemental Table 2. Characteristics of older adults with systolic blood pressure <140 
mmHg in 2011-2013, by systolic blood pressure in 2016–2017 and race.    
 
 White Black 



















Female sex 48.1% 59.9% <0.001 66.5% 70.9% 0.35 
Education        
Less than high school  9.3% 9.8% 0.001 21.4% 23.6% 0.71 
High school or vocational school 41.8% 52.1%  32.7% 29.1%  
College or higher 48.9% 38.1%  45.9% 47.3%  
Poor physical function  5.9% 8.8% 0.07 22.8% 21.6% 0.79 
Pre-frail or frail 47.3% 55.1% 0.01 51.6% 58.8% 0.16 
Mild cognitive impairment or 
dementia 17.6% 19.5% 0.40 14.2% 22.3% 0.04 
Depressive symptoms 5.1% 5.3% 0.89 6.8% 10.1% 0.22 
Medication adherence       
High 60.4% 61.7% 0.20 59.8% 53.4% 0.34 
Intermediate 38.7% 36.3%  36.3% 40.5%  
Low 0.9% 2.0%  3.9% 6.1%  
Hypertension duration,  









BMI category, kg/m2       
<25 17.8% 22.1% 0.08 8.9% 12.2% 0.05 
25-<30 40.5% 42.1%  34.2% 43.2%  
≥30 41.7% 35.8%  56.9% 44.6%  
Diabetes 28.6% 27.3% 0.64 38.8% 52.7% 0.006 
eGFR <60 mL/min/1.73 m2 26.6% 33.1% 0.02 22.8% 28.4% 0.20 
Prevalent coronary heart disease  18.7% 21.1% 0.33 8.9% 8.1% 0.78 
Prevalent stroke 2.6% 4.0% 0.18 3.9% 7.4% 0.12 
Prevalent heart failure 11.6% 10.5% 0.57 17.8% 17.6% 0.95 
SBP = Systolic Blood Pressure. eGFR = Estimated Glomerular Filtration Rate. BMI = Body Mass Index.   
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Supplemental Table 3. Characteristics of older adults with systolic blood pressure ≥140 
mmHg in 2011-2013, by systolic blood pressure in 2016–2017 and race.    
  
White Black 



















Female sex 48.6% 68.9% <0.001 75.6% 79.3% 0.52 
Education        
Less than high school  9.2% 10.0% 0.67 25.6% 23.0% 0.13 
High school or vocational school 44.4% 48.2%  25.6% 38.5%  
College or higher 46.5% 41.8%  48.8% 38.5%  
Poor physical function  11.3% 7.6% 0.22 26.7% 19.3% 0.19 
Pre-frail or frail 50.7% 51.8% 0.84 51.2% 54.8% 0.60 
Mild cognitive impairment or 
dementia 23.9% 20.3% 0.40 14.0% 22.2% 0.13 
Depressive symptoms 4.2% 5.6% 0.56 8.1% 14.8% 0.14 
Medication adherence       
High 63.4% 61.4% 0.59 55.8% 51.9% 0.57 
Intermediate 35.9% 36.7%  38.4% 44.4%  
Low 0.7% 2.0%  5.8% 3.7%  
Hypertension duration,  









BMI category, kg/m2       
<25 18.3% 25.5% 0.26 15.1% 14.8% 0.99 
25-<30 44.4% 40.2%  36.0% 37.0%  
≥30 37.3% 34.3%  48.8% 48.1%  
Diabetes 28.2% 25.5% 0.56 38.4% 43.7% 0.43 
eGFR <60 mL/min/1.73 m2 38.7% 31.9% 0.17 17.4% 30.4% 0.03 
Prevalent coronary heart disease 19.7% 15.9% 0.34 14.0% 8.1% 0.17 
Prevalent stroke 2.1% 4.0% 0.32 4.7% 5.9% 0.68 
Prevalent heart failure 14.8% 11.6% 0.36 17.4% 20.0% 0.64 
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Supplemental Table 1. Systolic blood pressure distribution and proportion of 
cardiovascular events prevented by reducing systolic blood pressure to <130 mmHg, by 
race.  




<130 64.7 (0.9) 51.2 (1.2) 
130-134 9.7 (0.6) 11.9 (0.7) 
135-139 6.9 (0.4) 8.8 (0.6) 
140-144 5.8 (0.5) 6.9 (0.5) 
145-149 3.9 (0.3) 5.0 (0.5) 
150-154 3.0 (0.4) 4.6 (0.6) 
155-159 1.8 (0.2) 3.5 (0.5) 
≥160 4.2 (0.4) 8.1 (0.6) 
Total SBP ≥130  35.3 (0.9) 48.8 (1.2) 
Population attributable fraction (2.5, 97.5) 22.3 (20.9, 23.6) 30.3 (28.5, 32.1) 
In this analysis, we assume individuals with systolic blood pressure ≥130 have their systolic 
blood pressure reduced regardless of whether they are eligible for pharmacotherapy or lifestyle 
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